{"content":"<li class=\"n-box-item date-title\" data-end=\"1576558799\" data-start=\"1576472400\" data-txt=\"Monday, December 23, 2019\">Monday, December 16, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3526633\" data-ts=\"1576536324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526633-panic-in-coffee-markets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Panic in the coffee markets</a></h4><ul> <li>Coffee futures <font color=\"green\">soared 7%</font> today to $1.3895 per pound to mark the biggest rally in the commodity since 2015.</li> <li>An off-cycle crop year for Brazil combined with strong global demand sent prices soaring amid what one trader <a href=\"https://www.cnbc.com/2019/12/16/coffee-futures-prices-have-the-biggest-one-day-surge-since-2015.html\" target=\"_blank\">called</a> \"panic\" in the market. Robusta and Arabica coffee future prices rose.</li> <li>The iPath Series B Bloomberg Coffee Subindex Total Return ETN (NYSEARCA:<a href='https://seekingalpha.com/symbol/JO' title='iPath Series B Bloomberg Coffee Subindex Total Return ETN'>JO</a>) <font color=\"green\">rose 8.60%</font> on the day and is 21% higher YTD.</li> <li>Related stocks: Coffee Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/JVA' title='Coffee Holding Co., Inc.'>JVA</a>), Dunkin' Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/DNKN' title='Dunkin&#39; Brands Group, Inc.'>DNKN</a>), J.M Smucker (NYSE:<a href='https://seekingalpha.com/symbol/SJM' title='The J. M. Smucker Company'>SJM</a>), Tata Global Beverages (<a href='https://seekingalpha.com/symbol/TTAEY' title='Tata Global Beverages Ltd ADR'>OTC:TTAEY</a>), McDonald's (NYSE:<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a>), Costa Coffee (NYSE:<a href='https://seekingalpha.com/symbol/KO' title='The Coca-Cola Company'>KO</a>), Tim Hortons (NYSE:<a href='https://seekingalpha.com/symbol/QSR' title='Restaurant Brands International Inc.'>QSR</a>), Nestle (<a href='https://seekingalpha.com/symbol/NSRGY' title='Nestlé S.A.'>OTCPK:NSRGY</a>), Keurig Dr Pepper (NYSE:<a href='https://seekingalpha.com/symbol/KDP' title='Keurig Dr Pepper Inc.'>KDP</a>), Kraft Heinz (NASDAQ:<a href='https://seekingalpha.com/symbol/KHC' title='The Kraft Heinz Company'>KHC</a>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3526633\" data-linked=\"Panic in the coffee markets\" data-tweet=\"$JO $JVA $DNKN - Panic in the coffee markets https://seekingalpha.com/news/3526633-panic-in-coffee-markets?source=tweet\" data-url=\"https://seekingalpha.com/news/3526633-panic-in-coffee-markets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>81&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526657\" data-ts=\"1576535620\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526657-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/PRVL' title='Prevail Therapeutics Inc.'>PRVL</a> <font color=\"green\">+15.8%</font>. <a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a> <font color=\"green\">+2.8%</font>. <a href='https://seekingalpha.com/symbol/SFUN' title='Fang Holdings Limited'>SFUN</a> <font color=\"green\">+2.4%</font>. <a href='https://seekingalpha.com/symbol/ODP' title='Office Depot, Inc.'>ODP</a> <font color=\"green\">+2.3%</font>. <a href='https://seekingalpha.com/symbol/HEI' title='HEICO Corporation'>HEI</a> <font color=\"green\">+2.2%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/SPR' title='Spirit AeroSystems Holdings, Inc.'>SPR</a> <font color=\"red\">-5.5%</font>. <a href='https://seekingalpha.com/symbol/CYCN' title='Cyclerion Therapeutics, Inc.'>CYCN</a> <font color=\"red\">-1.9%</font><a href='https://seekingalpha.com/symbol/BGCP' title='BGC Partners, Inc.'>BGCP</a> <font color=\"red\">-1.5%</font>. <a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color=\"red\">-1.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526657\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$PRVL $NOAH $SFUN - After Hours Gainers / Losers https://seekingalpha.com/news/3526657-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526657-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526635\" data-ts=\"1576532702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBER\" target=\"_blank\">UBER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526635-judge-wont-order-uber-driver-reclassification\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Judge won&#39;t order Uber driver reclassification</a></h4><ul><li>Uber (NYSE:<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a>) gains after a district judge in California refuses to issue an order that the company reclassifies its drivers as employees.</li><li>The judge says the action is premature since arbitration agreements signed by drivers would likely diminish the number who could benefit from employee rights.</li><li>The court didn't completely throw out the case. The driver who filed the original complaint has the right to refile with his \"plausible claim\" that Uber didn't reimburse his business expenses.</li><li>Source: Bloomberg.</li><li>Uber shares are <font color=\"green\">up 1.5%</font> after hours to $30.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526635\" data-linked=\"Judge won&#39;t order Uber driver reclassification\" data-tweet=\"$UBER - Judge won&#39;t order Uber driver reclassification https://seekingalpha.com/news/3526635-judge-wont-order-uber-driver-reclassification?source=tweet\" data-url=\"https://seekingalpha.com/news/3526635-judge-wont-order-uber-driver-reclassification\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526628\" data-ts=\"1576532212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACER\" target=\"_blank\">ACER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526628-acer-therapeutics-up-18-after-hours-on-advancement-of-acerminus-001-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acer Therapeutics up 18% after hours on advancement of ACER-001 study</a></h4><ul><li>Thinly traded nano cap Acer Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACER' title='Acer Therapeutics Inc.'>ACER</a>) is up <font color=\"green\">18% </font>after hours in reaction to its <a href=\"https://seekingalpha.com/pr/17729388-acer-therapeutics-announces-full-enrollment-of-part-b-in-acerminus-001-pivotal\" target=\"_blank\">announcement </a>of full enrollment in Part B of a pivotal study evaluating candidate ACER-001 (sodium phenylbutyrate) for the treatment of urea cycle disorders.</li><li>The primary of objective of Part B is bioequivalence to Horizon Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Therapeutics Public Limited Company'>HZNP</a>) <a href=\"https://www.hzndocs.com/BUPHENYL-Prescribing-Information.pdf\" target=\"_blank\">Buphenyl </a>in 36 healthy subjects.</li><li>The company plans to pursue U.S. approval via the abbreviated 505(b)(2) pathway.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526628\" data-linked=\"Acer Therapeutics up 18% after hours on advancement of ACER-001 study\" data-tweet=\"$ACER $HZNP - Acer Therapeutics up 18% after hours on advancement of ACER-001 study https://seekingalpha.com/news/3526628-acer-therapeutics-up-18-after-hours-on-advancement-of-acerminus-001-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3526628-acer-therapeutics-up-18-after-hours-on-advancement-of-acerminus-001-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526600\" data-ts=\"1576531359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTO\" target=\"_blank\">APTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526600-aptose-bio-launches-equity-offering-shares-down-13-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptose Bio launches equity offering; shares down 13% after hours</a></h4><ul><li>Aptose Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>) commences a <a href=\"https://seekingalpha.com/pr/17729439-aptose-announces-proposed-public-offering-of-common-shares\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li><li>Shares down <font color=\"red\">13%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526600\" data-linked=\"Aptose Bio launches equity offering; shares down 13% after hours\" data-tweet=\"$APTO - Aptose Bio launches equity offering; shares down 13% after hours https://seekingalpha.com/news/3526600-aptose-bio-launches-equity-offering-shares-down-13-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3526600-aptose-bio-launches-equity-offering-shares-down-13-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526592\" data-ts=\"1576531066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEIP\" target=\"_blank\">MEIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526592-mei-pharma-readies-equity-offering-shares-down-26-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MEI Pharma readies equity offering; shares down 26% after hours</a></h4><ul><li>MEI Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/MEIP' title='MEI Pharma, Inc.'>MEIP</a>) slumps <font color=\"red\">26%</font> after hours in reaction to its planned <a href=\"https://seekingalpha.com/pr/17729366-mei-pharma-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526592\" data-linked=\"MEI Pharma readies equity offering; shares down 26% after hours\" data-tweet=\"$MEIP - MEI Pharma readies equity offering; shares down 26% after hours https://seekingalpha.com/news/3526592-mei-pharma-readies-equity-offering-shares-down-26-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3526592-mei-pharma-readies-equity-offering-shares-down-26-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526582\" data-ts=\"1576530906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGIO\" target=\"_blank\">AGIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526582-agios-pharmas-tibsovo-nabs-accelerated-review-in-u-s-for-type-of-mds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agios Pharma&#39;s Tibsovo nabs accelerated review in U.S. for type of MDS</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17729359-agios-receives-fda-breakthrough-therapy-designation-for-tibsovo-ivosidenib-for-treatment-of\" target=\"_blank\">designates </a>Agios Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a>) Tibsovo (ivosidenib) a Breakthrough Therapy for the treatment of adult patients with relapsed/refractory myelodysplastic syndrome &#40;MDS&#41; with a susceptible IDH1 mutation.</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li><li>Tibsovo is currently approved in the U.S. for certain IDH1-positive leukemia patients.</li><li>Shares up <font color=\"green\">6%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526582\" data-linked=\"Agios Pharma&#39;s Tibsovo nabs accelerated review in U.S. for type of MDS\" data-tweet=\"$AGIO - Agios Pharma&#39;s Tibsovo nabs accelerated review in U.S. for type of MDS https://seekingalpha.com/news/3526582-agios-pharmas-tibsovo-nabs-accelerated-review-in-u-s-for-type-of-mds?source=tweet\" data-url=\"https://seekingalpha.com/news/3526582-agios-pharmas-tibsovo-nabs-accelerated-review-in-u-s-for-type-of-mds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526571\" data-ts=\"1576530205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPZM\" target=\"_blank\">EPZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526571-fda-ad-com-this-week-for-epizymes-tazemetostat-for-epitheloid-sarcoma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Ad Com this week for Epizyme&#39;s tazemetostat for epitheloid sarcoma</a></h4><ul><li>The FDA's Oncologic Drugs Advisory Committee will <a href=\"https://www.fda.gov/advisory-committees/updated-public-participation-information-december-18-2019-meeting-oncologic-drugs-advisory-committee\" target=\"_blank\">meet</a> on Wednesday, December 18, to review and discuss Epizyme's (<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme, Inc.'>EPZM</a> <font color=\"green\">+3.6%</font>) marketing application for tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.</li><li><a href=\"https://www.fda.gov/advisory-committees/updated-public-participation-information-december-18-2019-meeting-oncologic-drugs-advisory-committee#event-materials\" target=\"_blank\">Meeting materials</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3526571\" data-linked=\"FDA Ad Com this week for Epizyme&#39;s tazemetostat for epitheloid sarcoma\" data-tweet=\"$EPZM - FDA Ad Com this week for Epizyme&#39;s tazemetostat for epitheloid sarcoma https://seekingalpha.com/news/3526571-fda-ad-com-this-week-for-epizymes-tazemetostat-for-epitheloid-sarcoma?source=tweet\" data-url=\"https://seekingalpha.com/news/3526571-fda-ad-com-this-week-for-epizymes-tazemetostat-for-epitheloid-sarcoma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526568\" data-ts=\"1576529819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526568-ad-com-tuesday-for-astrazenecas-lynparza-for-maintenance-of-pancreatic-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad Com Tuesday for AstraZeneca&#39;s Lynparza for maintenance of pancreatic cancer</a></h4><ul><li>The FDA's Oncologic Drugs Advisory Committee will <a href=\"https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-public-participation-information-december-17-2019-meeting-oncologic-drugs-advisory-committee\" target=\"_blank\">meet </a>on Tuesday, December 17, to review and discuss AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a> <font color=\"green\">+2%</font>) marketing application for Lynparza (olaparib) for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic adenocarcinoma of the pancreas whose disease has not progressed on first-line platinum-based chemotherapy.</li><li><a href=\"https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-public-participation-information-december-17-2019-meeting-oncologic-drugs-advisory-committee#event-materials\" target=\"_blank\">Meeting materials</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3526568\" data-linked=\"Ad Com Tuesday for AstraZeneca&#39;s Lynparza for maintenance of pancreatic cancer\" data-tweet=\"$AZN - Ad Com Tuesday for AstraZeneca&#39;s Lynparza for maintenance of pancreatic cancer https://seekingalpha.com/news/3526568-ad-com-tuesday-for-astrazenecas-lynparza-for-maintenance-of-pancreatic-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3526568-ad-com-tuesday-for-astrazenecas-lynparza-for-maintenance-of-pancreatic-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526565\" data-ts=\"1576528890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526565-select-shipping-stocks-break-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Select shipping stocks break higher</a></h4><ul> <li>The shipping sector is seeing some gains today after investors digest the cooling off of the U.S.-China trade war.</li> <li>The biggest gainers on the day include TORM (<a href='https://seekingalpha.com/symbol/TORM' title='TOR Minerals International, Inc.'>OTCPK:TORM</a>), Overseas Shipholding Group (<a href='https://seekingalpha.com/symbol/OSG' title='Overseas Shipholding Group, Inc.'>OSG</a> <font color='green'>+7.6%</font>), Matson (<a href='https://seekingalpha.com/symbol/MATX' title='Matson, Inc.'>MATX</a> <font color='green'>+6.1%</font>), Nordic American Tankers (<a href='https://seekingalpha.com/symbol/NAT' title='Nordic American Tankers Limited'>NAT</a> <font color='green'>+3.7%</font>), Navios Maritime Containers (<a href='https://seekingalpha.com/symbol/NMCI' title='Navios Maritime Containers L.P.'>NMCI</a> <font color='green'>+3%</font>), Danaos (<a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a> <font color='green'>+2.6%</font>) and DHT Holdings (<a href='https://seekingalpha.com/symbol/DHT' title='DHT Holdings, Inc.'>DHT</a> <font color='green'>+2.4%</font>).</li> <li>The Invesco Shipping ETF(NYSEARCA:<a href='https://seekingalpha.com/symbol/SEA' title='Invesco Shipping ETF'>SEA</a>) is <font color=\"green\">up 1.35%</font> on the day to top the <font color=\"green\">0.80% return</font> of the S&amp;P 500 Index.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526565\" data-linked=\"Select shipping stocks break higher\" data-tweet=\"$TORM $OSG $MATX - Select shipping stocks break higher https://seekingalpha.com/news/3526565-select-shipping-stocks-break-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3526565-select-shipping-stocks-break-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526564\" data-ts=\"1576528886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526564-tonix-pharma-up-10-on-development-plan-for-daily-mdd-pill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma up 10% on development plan for once-daily MDD pill</a></h4><ul><li>Nano cap Tonix Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color=\"green\">+10.4%</font>) is up on 80% higher volume in reaction to its <a href=\"https://seekingalpha.com/pr/17729321-tonix-pharmaceuticals-announces-plan-to-develop-tnxminus-601-cr-tablets-for-daily-treatment\" target=\"_blank\">plan to develop</a> TNX-601 CR (tianeptine oxalate controlled release) tablets for the once-daily treatment of major depressive disorder &#40;MDD&#41; and posttraumatic stress disorder &#40;PTSD&#41;.</li><li>The first efficacy study ex-U.S. should launch in 2020. The company expects to have a pre-IND meeting with the FDA in H1 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526564\" data-linked=\"Tonix Pharma up 10% on development plan for once-daily MDD pill\" data-tweet=\"$TNXP - Tonix Pharma up 10% on development plan for once-daily MDD pill https://seekingalpha.com/news/3526564-tonix-pharma-up-10-on-development-plan-for-daily-mdd-pill?source=tweet\" data-url=\"https://seekingalpha.com/news/3526564-tonix-pharma-up-10-on-development-plan-for-daily-mdd-pill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526561\" data-ts=\"1576526850\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526561-amazon-bans-merchants-from-fedex-ground-delivery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon bans merchants from FedEx ground delivery</a></h4><ul><li>Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+0.4%</font>) is blocking third-party sellers from using FedEx's (<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a> <font color='red'>-1.2%</font>) Ground and Home delivery for Prime shipments, according to a merchant email viewed by <a href=\"https://www.wsj.com/articles/amazon-blocks-sellers-from-using-fedex-ground-for-prime-shipments-11576525190\" target=\"_blank\">the WSJ</a>.</li><li>The tech giant cites a decline in performance heading into the holiday season.</li><li>The ban starts this week and will continue \"until the delivery performance of these ship methods improves.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3526561\" data-linked=\"Amazon bans merchants from FedEx ground delivery\" data-tweet=\"$AMZN $FDX - Amazon bans merchants from FedEx ground delivery https://seekingalpha.com/news/3526561-amazon-bans-merchants-from-fedex-ground-delivery?source=tweet\" data-url=\"https://seekingalpha.com/news/3526561-amazon-bans-merchants-from-fedex-ground-delivery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>87&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526560\" data-ts=\"1576526694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526560-verb-technology-and-gridsum-among-tech-gainers-communications-systems-and-live-ventures-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verb Technology and Gridsum among Tech gainers; Communications Systems and Live Ventures among losers</a></h4><ul><li><b>Gainers: </b>Verb Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/VERB' title='Verb Technology Company, Inc.'>VERB</a>) <font color=\"green\">+18%</font>. Gridsum (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding Inc.'>GSUM</a>) <font color=\"green\">+14%</font>. SMART Global (NASDAQ:<a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings, Inc.'>SGH</a>) <font color=\"green\">+13%</font>. Perion Network (NASDAQ:<a href='https://seekingalpha.com/symbol/PERI' title='Perion Network Ltd.'>PERI</a>) <font color=\"green\">+11%</font>. Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc.'>MAXR</a>) <font color=\"green\">+10%</font>.</li><li><b>Losers: </b>Communications Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/JCS' title='Communications Systems, Inc.'>JCS</a>) <font color=\"red\">-23%</font>. Live Ventures (NASDAQ:<a href='https://seekingalpha.com/symbol/LIVE' title='Live Ventures Incorporated'>LIVE</a>) <font color=\"red\">-15%</font>. GTT Communications (NYSE:<a href='https://seekingalpha.com/symbol/GTT' title='GTT Communications, Inc.'>GTT</a>) <font color=\"red\">-10%</font>. YayYo (NASDAQ:<a href='https://seekingalpha.com/symbol/YAYO' title='YayYo, Inc.'>YAYO</a>) <font color=\"red\">-9%</font>. Inseego (NASDAQ:<a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526560\" data-linked=\"Verb Technology and Gridsum among Tech gainers; Communications Systems and Live Ventures among losers\" data-tweet=\"$VERB $GSUM $SGH - Verb Technology and Gridsum among Tech gainers; Communications Systems and Live Ventures among losers https://seekingalpha.com/news/3526560-verb-technology-and-gridsum-among-tech-gainers-communications-systems-and-live-ventures-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3526560-verb-technology-and-gridsum-among-tech-gainers-communications-systems-and-live-ventures-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526557\" data-ts=\"1576526412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526557-fedex-lower-after-amazon-bans-certain-deliveries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx lower after Amazon bans certain deliveries</a></h4><ul> <li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) turns lower after Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) points to a <a href=\"https://www.wsj.com/articles/amazon-blocks-sellers-from-using-fedex-ground-for-prime-shipments-11576525190\" target=\"_blank\">decline</a> in the shipper's performance heading just ahead of the final holiday push.</li> <li>Amazon has reportedly steered third-party sellers from using FedEx's ground delivery network due to the issues, although they can still use FedEx's Express service or FedEx Ground for non-Prime shipments.</li> <li>It's unclear how long the FedEx ground delivery ban will be in place for Amazon merchants.</li> <li>Shares of FDX are <font color=\"red\">down 1.33%</font> after being in positive territory for most of the session.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526557\" data-linked=\"FedEx lower after Amazon bans certain deliveries\" data-tweet=\"$FDX $AMZN - FedEx lower after Amazon bans certain deliveries https://seekingalpha.com/news/3526557-fedex-lower-after-amazon-bans-certain-deliveries?source=tweet\" data-url=\"https://seekingalpha.com/news/3526557-fedex-lower-after-amazon-bans-certain-deliveries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526552\" data-ts=\"1576524612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEET\" target=\"_blank\">MEET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526552-meet-group-see-8-share-in-sale-roth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Meet Group could see $8/share in a sale - Roth</a></h4><ul><li>Roth analyst Darren Aftahi says Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) could be valued at $7-8 per share in a potential sale based on its peer group valuation.</li><li>Aftahi thinks NuCom's \"interest likely revolves around implementing live streaming across its dating apps\" and potential synergies with European audiences.</li><li>Roth maintains a Buy rating and $6.50 price target on MEET. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/MEET/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>MEET shares are <font color=\"green\">up 5.6%</font> to $5.34.</li><li>Related: Earlier today, <a href=\"https://seekingalpha.com/news/3526518-meet-groupplus-5_7-on-acquisition-talks\" target=\"_blank\">Reuters reported</a> that Prosieben's NuCom had signaled an interest in acquiring Meet, but the talks are still in early stages.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526552\" data-linked=\"Meet Group could see $8/share in a sale - Roth\" data-tweet=\"$MEET - Meet Group could see $8/share in a sale - Roth https://seekingalpha.com/news/3526552-meet-group-see-8-share-in-sale-roth?source=tweet\" data-url=\"https://seekingalpha.com/news/3526552-meet-group-see-8-share-in-sale-roth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526550\" data-ts=\"1576523831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526550-fortinet-gains-on-google-cloud-integrations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortinet gains on Google Cloud integrations</a></h4><ul><li>Fortinet (<a href='https://seekingalpha.com/symbol/FTNT' title='Fortinet, Inc.'>FTNT</a> <font color='green'>+1.2%</font>) <a href=\"https://seekingalpha.com/pr/17729175-fortinet-tightens-partnership-google-cloud-to-provide-advanced-cloud-security-and-accelerate\" target=\"_blank\">extends its integration</a> with Google Cloud (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a> <font color='green'>+0.9%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a> <font color='green'>+0.9%</font>) to include a new reference architecture to help migrating customers connect distributed branches to GCP with Fortinet\u2019s Secure SD-WAN solution.</li><li>FTNT is also releasing the FortiWeb Cloud WAF-as-a-Service in the Google Cloud Marketplace.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526550\" data-linked=\"Fortinet gains on Google Cloud integrations\" data-tweet=\"$FTNT $GOOG $GOOGL - Fortinet gains on Google Cloud integrations https://seekingalpha.com/news/3526550-fortinet-gains-on-google-cloud-integrations?source=tweet\" data-url=\"https://seekingalpha.com/news/3526550-fortinet-gains-on-google-cloud-integrations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526549\" data-ts=\"1576523150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526549-camber-energy-and-tetra-technologies-among-energy-materials-gainers-international-flavors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Camber Energy and TETRA Technologies among Energy/Materials gainers; International Flavors &amp; Fragrances and TuanChe among losers</a></h4><ul><li><b>Gainers: </b>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+16%</font>. TETRA Technologies (NYSE:<a href='https://seekingalpha.com/symbol/TTI' title='TETRA Technologies, Inc.'>TTI</a>) <font color=\"green\">+16%</font>. Southwestern Energy (NYSE:<a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Company'>SWN</a>) <font color=\"green\">+11%</font>. WPX Energy (NYSE:<a href='https://seekingalpha.com/symbol/WPX' title='WPX Energy, Inc.'>WPX</a>) <font color=\"green\">+10%</font>. Range Resources (NYSE:<a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a>) <font color=\"green\">+10%</font>.</li><li><b>Losers: </b>International Flavors &amp; Fragrances (NYSE:<a href='https://seekingalpha.com/symbol/IFF' title='International Flavors & Fragrances Inc.'>IFF</a>) <font color=\"red\">-10%</font>. TuanChe (NASDAQ:<a href='https://seekingalpha.com/symbol/TC' title='TuanChe Limited'>TC</a>) <font color=\"red\">-8%</font>. Franchise Group (NASDAQ:<a href='https://seekingalpha.com/symbol/FRG' title='Franchise Group, Inc.'>FRG</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526549\" data-linked=\"Camber Energy and TETRA Technologies among Energy/Materials gainers; International Flavors &amp; Fragrances and TuanChe among losers\" data-tweet=\"$CEI $TTI $SWN - Camber Energy and TETRA Technologies among Energy/Materials gainers; International Flavors &amp; Fragrances and TuanChe among losers https://seekingalpha.com/news/3526549-camber-energy-and-tetra-technologies-among-energy-materials-gainers-international-flavors?source=tweet\" data-url=\"https://seekingalpha.com/news/3526549-camber-energy-and-tetra-technologies-among-energy-materials-gainers-international-flavors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526548\" data-ts=\"1576523081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526548-theater-sector-rallies-on-merger-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Theater sector rallies on merger news</a></h4><ul> <li>AMC Entertainment (<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc.'>AMC</a> <font color='green'>+3.6%</font>) and Cinemark Holdings (<a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc.'>CNK</a> <font color='green'>+2.2%</font>) are both higher after Cineworld's (<a href='https://seekingalpha.com/symbol/CNWGY' title='Cineworld Group PLC ADR'>OTC:CNWGY</a>) big acquisition of Cineplex narrows the number of operators in North America even further.</li> <li>Macquarie thinks the takeover premium that Cineworld was willing to pay should help support valuation on AMC and CNK.</li><li>Cineworld closed u<font color=\"green\">p 2.47%</font> in London today.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3526372-cineworld-swallows-up-cineplex\" target=\"_blank\">Cineworld swallows up Cineplex</a> (Dec. 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526548\" data-linked=\"Theater sector rallies on merger news\" data-tweet=\"$AMC $CNK $CNWGY - Theater sector rallies on merger news https://seekingalpha.com/news/3526548-theater-sector-rallies-on-merger-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3526548-theater-sector-rallies-on-merger-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526545\" data-ts=\"1576522116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADIL\" target=\"_blank\">ADIL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526545-adial-pharma-up-18-on-new-u-s-patent-covering-lead-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adial Pharma up 18% on new U.S. patent covering lead drug</a></h4><ul><li>Thinly traded nano cap Adial Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ADIL' title='Adial Pharmaceuticals, Inc.'>ADIL</a> <font color=\"green\">+18.2%</font>) is up on a healthy 30x surge in volume, about 1.3M shares, in reaction to its receipt of a <a href=\"https://seekingalpha.com/pr/17728898-adial-pharmaceuticals-receives-notice-of-allowance-of-additional-patent-for-treatment-of\" target=\"_blank\">Notice of Allowance</a> from the USPTO for a method of use patent covering lead candidate AD04 for the treatment of alcoholism.</li><li>The patent covers a method of treating alcohol use disorder with AD04 in patients with a specific serotonin biomarker.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526545\" data-linked=\"Adial Pharma up 18% on new U.S. patent covering lead drug\" data-tweet=\"$ADIL - Adial Pharma up 18% on new U.S. patent covering lead drug https://seekingalpha.com/news/3526545-adial-pharma-up-18-on-new-u-s-patent-covering-lead-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/3526545-adial-pharma-up-18-on-new-u-s-patent-covering-lead-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526540\" data-ts=\"1576521399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEP\" target=\"_blank\">PEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526540-morgan-stanley-cools-on-pepsico\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley cools on PepsiCo</a></h4><ul> <li>Morgan Stanley lowers PepsiCo (<a href='https://seekingalpha.com/symbol/PEP' title='PepsiCo, Inc.'>PEP</a> <font color='red'>-0.5%</font>) to an Equal-weight rating from Overweight on its view that the snacks business is fully valued.</li> <li>Analyst Dara Mohsenian and team also see some risk to PepsiCo's 2020 revenue targets.</li> <li>Shares of PepsiCo are up 24.21% YTD and trade at 16X the consensus 2020 EPS forecast.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526540\" data-linked=\"Morgan Stanley cools on PepsiCo\" data-tweet=\"$PEP - Morgan Stanley cools on PepsiCo https://seekingalpha.com/news/3526540-morgan-stanley-cools-on-pepsico?source=tweet\" data-url=\"https://seekingalpha.com/news/3526540-morgan-stanley-cools-on-pepsico\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526537\" data-ts=\"1576520938\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SITM\" target=\"_blank\">SITM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526537-sitimeplus-5-on-wave-of-bull-starts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SiTime +5% on wave of bull starts</a></h4><ul><li>Analysts come emerge on SiTime (NASDAQ:<a href='https://seekingalpha.com/symbol/SITM' title='SiTime Corporation'>SITM</a>) in the first actions since the company's IPO last month.</li><li>Barclays (Overweight, $25 target) thinks SiTime has \"succeeded where others have failed\" in moving away from incumbent quartz crystal-based timing solutions, giving SITM a competitive advantage.</li><li>Raymond James (Outperform, $24) notes the coming demand from the 5G infrastructure market, \"creating an opportunity for SITM to displace legacy crystal suppliers.\"</li><li>Roth (Buy, $25) cites SITM's competitive advantage and valuation, which offers a significant discount to its peers.</li><li>SITM shares are <font color=\"green\">up 4.9%</font> to $20.60.</li><li>The company has a Very Bullish average <a href=\"https://seekingalpha.com/symbol/SITM/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526537\" data-linked=\"SiTime +5% on wave of bull starts\" data-tweet=\"$SITM - SiTime +5% on wave of bull starts https://seekingalpha.com/news/3526537-sitimeplus-5-on-wave-of-bull-starts?source=tweet\" data-url=\"https://seekingalpha.com/news/3526537-sitimeplus-5-on-wave-of-bull-starts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526536\" data-ts=\"1576520514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZYNE\" target=\"_blank\">ZYNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526536-zynerba-up-21-on-renewed-optimism-zygel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zynerba up 21% on renewed optimism with Zygel</a></h4><ul><li>Zynerba Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a> <font color=\"green\">+21%</font>) jumps on more than 50% higher volume in reaction to positive comments from Canaccord Genuity related to Zygel (transdermal cannabidiol gel) for the potential treatment of developmental and epileptic encephalopathies, a group of rare pediatric epilepsy syndromes including Dravet and Lennox-Gastaut.</li><li>Analyst Sumant Kulkarni liked what he heard at an investor conference featuring the principal investigator in the Phase 2 BELIEVE-1 study who said Zygel was actually well-tolerated over the six-month treatment period and the reported adverse events were not unusual for that particular patient population.</li><li>Shares sold off three months ago after the company <a href=\"https://seekingalpha.com/news/3500078-zynerba-down-4-premarket-on-possible-zygel-safety-signal\" target=\"_blank\">reported</a> results from the trial that included a high rate (96%) of treatment-emergent adverse events. Shares were down over <font color=\"red\">50%</font> since then before today's action.</li><li>The company plans to meet with the FDA in H1 2020 to discuss the results from BELIEVE-1 aimed at informing a Phase 3 trial.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526536\" data-linked=\"Zynerba up 21% on renewed optimism with Zygel\" data-tweet=\"$ZYNE - Zynerba up 21% on renewed optimism with Zygel https://seekingalpha.com/news/3526536-zynerba-up-21-on-renewed-optimism-zygel?source=tweet\" data-url=\"https://seekingalpha.com/news/3526536-zynerba-up-21-on-renewed-optimism-zygel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526535\" data-ts=\"1576519990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GV\" target=\"_blank\">GV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526535-goldfield-secures-two-major-electrical-construction-contracts-sharesplus-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldfield secures two major electrical construction contracts; shares +21%</a></h4><ul><li>Goldfield (<a href='https://seekingalpha.com/symbol/GV' title='The Goldfield Corporation'>GV</a> <font color=\"green\">+21.6%</font>) has been <a href=\"https://seekingalpha.com/pr/17728395-goldfield-wins-major-electrical-construction-mandates\" target=\"_blank\">awarded</a> two significant contracts to construct new and rebuild transmission lines in Florida. The projects include transmission, substation and foundation construction services.</li><li>These projects are expected to produce ~$50M in revenue through 2021 of which ~$35M is expected to be completed during 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526535\" data-linked=\"Goldfield secures two major electrical construction contracts; shares +21%\" data-tweet=\"$GV - Goldfield secures two major electrical construction contracts; shares +21% https://seekingalpha.com/news/3526535-goldfield-secures-two-major-electrical-construction-contracts-sharesplus-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3526535-goldfield-secures-two-major-electrical-construction-contracts-sharesplus-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526534\" data-ts=\"1576519502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526534-intl-fcstone-and-ezcorp-among-financial-gainers-cohen-and-xp-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">INTL FCStone and EZCORP among Financial gainers; Cohen and XP among losers</a></h4><ul><li><b>Gainers: </b>INTL FCStone (NASDAQ:<a href='https://seekingalpha.com/symbol/INTL' title='INTL FCStone Inc.'>INTL</a>) <font color=\"green\">+9%</font>. EZCORP (NASDAQ:<a href='https://seekingalpha.com/symbol/EZPW' title='EZCORP, Inc.'>EZPW</a>) <font color=\"green\">+8%</font>. IRSA Inversiones y Representaciones Sociedad Anonima (NYSE:<a href='https://seekingalpha.com/symbol/IRS' title='IRSA Inversiones y Representaciones Sociedad Anónima'>IRS</a>) <font color=\"green\">+7%</font>. EverQuote (NASDAQ:<a href='https://seekingalpha.com/symbol/EVER' title='EverQuote, Inc.'>EVER</a>) <font color=\"green\">+6%</font>. CorePoint Lodging (NYSE:<a href='https://seekingalpha.com/symbol/CPLG' title='CorePoint Lodging Inc.'>CPLG</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Cohen (NYSEMKT:<a href='https://seekingalpha.com/symbol/COHN' title='Cohen & Company Inc.'>COHN</a>) <font color=\"red\">-12%</font>. XP Investimentos (NASDAQ:<a href='https://seekingalpha.com/symbol/XP' title='XP'>XP</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526534\" data-linked=\"INTL FCStone and EZCORP among Financial gainers; Cohen and XP among losers\" data-tweet=\"$INTL $EZPW $IRS - INTL FCStone and EZCORP among Financial gainers; Cohen and XP among losers https://seekingalpha.com/news/3526534-intl-fcstone-and-ezcorp-among-financial-gainers-cohen-and-xp-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526534-intl-fcstone-and-ezcorp-among-financial-gainers-cohen-and-xp-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526531\" data-ts=\"1576519367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526531-industrial-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Industrial - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>The Goldfield (NYSEMKT:<a href='https://seekingalpha.com/symbol/GV' title='The Goldfield Corporation'>GV</a>) <font color=\"green\">+24%</font>. SIFCO Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/SIF' title='SIFCO Industries, Inc.'>SIF</a>) <font color=\"green\">+20%</font>. Titan International (NYSE:<a href='https://seekingalpha.com/symbol/TWI' title='Titan International, Inc.'>TWI</a>) <font color=\"green\">+15%</font>. Hebron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a>) <font color=\"green\">+9%</font>. Granite Construction (NYSE:<a href='https://seekingalpha.com/symbol/GVA' title='Granite Construction Incorporated'>GVA</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Tutor Perini (NYSE:<a href='https://seekingalpha.com/symbol/TPC' title='Tutor Perini Corporation'>TPC</a>) <font color=\"red\">-17%</font>. Carpenter Technology (NYSE:<a href='https://seekingalpha.com/symbol/CRS' title='Carpenter Technology Corporation'>CRS</a>) <font color=\"red\">-9%</font>. China Ceramics (NASDAQ:<a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a>) <font color=\"red\">-8%</font>. Air Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/AIRI' title='Air Industries Group'>AIRI</a>) <font color=\"red\">-8%</font>. Forterra (NASDAQ:<a href='https://seekingalpha.com/symbol/FRTA' title='Forterra, Inc.'>FRTA</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526531\" data-linked=\"Industrial - Top 5 Gainers / Losers\" data-tweet=\"$GV $SIF $TWI - Industrial - Top 5 Gainers / Losers https://seekingalpha.com/news/3526531-industrial-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526531-industrial-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526528\" data-ts=\"1576519139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526528-palo-altoplus-1_3-on-google-cloud-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto +1.3% on Google Cloud partnership</a></h4><ul><li>The companies will collaborate on new offerings to market and run several Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks, Inc.'>PANW</a>) services on Google Cloud (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a> <font color='green'>+0.9%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a> <font color='green'>+0.9%</font>).</li><li>The solutions will include developing a security framework for multi-cloud environments with Google's Anthos platform and integrating Google Cloud's Event Threat Detection and PANW's AutoFocus threat intelligence.</li><li>The new solutions will be available in H1 2020.</li><li>Palo Alto shares are <font color=\"green\">up 1.3%</font> to $229.80.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526528\" data-linked=\"Palo Alto +1.3% on Google Cloud partnership\" data-tweet=\"$PANW $GOOG $GOOGL - Palo Alto +1.3% on Google Cloud partnership https://seekingalpha.com/news/3526528-palo-altoplus-1_3-on-google-cloud-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3526528-palo-altoplus-1_3-on-google-cloud-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526525\" data-ts=\"1576518092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526525-zyne-sesn-axsm-and-trnx-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ZYNE, SESN, AXSM and TRNX among midday movers</a></h4><ul><li><strong>Gainers: </strong>Mirum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MIRM' title='Mirum Pharmaceuticals, Inc.'>MIRM</a>) <font color=\"green\">+110%</font>.</li><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+74%</font>.</li><li>The Goldfield (NYSEMKT:<a href='https://seekingalpha.com/symbol/GV' title='The Goldfield Corporation'>GV</a>) <font color=\"green\">+24%</font>.</li><li>SIFCO Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/SIF' title='SIFCO Industries, Inc.'>SIF</a>) <font color=\"green\">+23%</font>.</li><li>BioXcel Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BTAI' title='BioXcel Therapeutics, Inc.'>BTAI</a>) <font color=\"green\">+21%</font>.</li><li>La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Company'>LJPC</a>) <font color=\"green\">+20%</font>.</li><li>Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a>) <font color=\"green\">+19%</font>.</li><li>Relmada Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RLMD' title='Relmada Therapeutics, Inc.'>RLMD</a>) <font color=\"green\">+18%</font>.</li><li>Cyclerion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CYCN' title='Cyclerion Therapeutics, Inc.'>CYCN</a>) <font color=\"green\">+18%</font>.</li><li>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+17%</font>.</li><li><strong>Losers:</strong> Wave Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/WVE' title='Wave Life Sciences Ltd.'>WVE</a>) <font color=\"red\">-54%</font>.</li><li>Gossamer Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/GOSS' title='Gossamer Bio, Inc.'>GOSS</a>) <font color=\"red\">-37%</font>.</li><li>Communications Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/JCS' title='Communications Systems, Inc.'>JCS</a>) <font color=\"red\">-27%</font>.</li><li>Kewaunee Scientific (NASDAQ:<a href='https://seekingalpha.com/symbol/KEQU' title='Kewaunee Scientific Corporation'>KEQU</a>) <font color=\"red\">-23%</font>.</li><li>LMP Automotive (NASDAQ:<a href='https://seekingalpha.com/symbol/LMPX' title='LMP Automotive Holdings, Inc.'>LMPX</a>) <font color=\"red\">-19%</font>.</li><li>Tutor Perini (NYSE:<a href='https://seekingalpha.com/symbol/TPC' title='Tutor Perini Corporation'>TPC</a>) <font color=\"red\">-18%</font>.</li><li>Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) <font color=\"red\">-17%</font>.</li><li>Sesen Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SESN' title='Sesen Bio, Inc.'>SESN</a>) <font color=\"red\">-17%</font>.</li><li>Taronis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TRNX' title='Taronis Technologies, Inc.'>TRNX</a>) <font color=\"red\">-16%</font>.</li><li>Live Ventures (NASDAQ:<a href='https://seekingalpha.com/symbol/LIVE' title='Live Ventures Incorporated'>LIVE</a>) <font color=\"red\">-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526525\" data-linked=\"ZYNE, SESN, AXSM and TRNX among midday movers\" data-tweet=\"$MIRM $AXSM $GV - ZYNE, SESN, AXSM and TRNX among midday movers https://seekingalpha.com/news/3526525-zyne-sesn-axsm-and-trnx-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526525-zyne-sesn-axsm-and-trnx-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526524\" data-ts=\"1576517675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SO\" target=\"_blank\">SO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526524-southern-co-rises-1_5-bofa-sees-constructive-outcome-of-rate-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southern Co. rises 1.5% as BofA sees &#39;constructive outcome&#39; of rate case</a></h4><ul><li>Southern Co. (NYSE:<a href='https://seekingalpha.com/symbol/SO' title='The Southern Company'>SO</a>)<font color=\"green\"> advances 1.5%</font> after Bank of America analyst Julien Dumoulin-Smith continues to expect an \"overall constructive outcome\" from the Georgia Power rate case tomorrow.</li><li>Boosts price target to $65 from $62; maintains neutral recommendation.</li><li>Guggenheim said in an earlier note that Georgia Power seeks to boost its annual rates through 2022.</li><li><a href=\"https://seekingalpha.com/symbol/SO/ratings/quant-ratings\" target=\"_blank\">Quant rating</a> on Southern is Neutral, the same as <a href=\"https://seekingalpha.com/symbol/SO/ratings/author-ratings#filter=all\" target=\"_blank\"> SA Authors' average rating</a>.</li><li>In the past six months,<a href=\"https://seekingalpha.com/symbol/SO/momentum/performance\" target=\"_blank\"> SO has climbed 10%</a>, outpacing the utilities sector median performance of 3.8% during the same period.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526524\" data-linked=\"Southern Co. rises 1.5% as BofA sees &#39;constructive outcome&#39; of rate case\" data-tweet=\"$SO - Southern Co. rises 1.5% as BofA sees &#39;constructive outcome&#39; of rate case https://seekingalpha.com/news/3526524-southern-co-rises-1_5-bofa-sees-constructive-outcome-of-rate-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3526524-southern-co-rises-1_5-bofa-sees-constructive-outcome-of-rate-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526523\" data-ts=\"1576517569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBER\" target=\"_blank\">UBER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526523-uber-eats-india-sale-inevitable-raymond-james\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uber Eats India sale &#39;inevitable&#39; - Raymond James</a></h4><ul><li>Uber (<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a> <font color='green'>+5.5%</font>) shares continue to gain on <a href=\"https://seekingalpha.com/news/3526325-uber-commits-to-bikes-selling-indian-food-delivery-unit\" target=\"_blank\">reports</a> the company will unload its Uber Eats India business to Zomato.</li><li>Raymond James analyst Justin Patterson says the sale appears inevitable given the service's third-place ranking in the region, which would take significant time and investment to improve.</li><li>Patterson says the sale to Zomato offers several benefits, including receiving a stake in the market leader, but also highlights that Uber didn't win the market, raising questions about the network strength and platform advantages.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526523\" data-linked=\"Uber Eats India sale &#39;inevitable&#39; - Raymond James\" data-tweet=\"$UBER - Uber Eats India sale &#39;inevitable&#39; - Raymond James https://seekingalpha.com/news/3526523-uber-eats-india-sale-inevitable-raymond-james?source=tweet\" data-url=\"https://seekingalpha.com/news/3526523-uber-eats-india-sale-inevitable-raymond-james\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526522\" data-ts=\"1576517338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526522-tesla-rallies-off-praise-from-noted-bear\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla rallies off praise from noted bear</a></h4><ul> <li>Tesla (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+6.4%</font>) is riding higher after Credit Suisse issues some positive comments on the EV automaker even as it keeps an Underperform rating in place.</li> <li>\"We believe Tesla is leading in the areas that will likely define the future of carmaking \u2013 software and electrification,\" notes analyst Dan Levy.</li> <li>Looking ahead, the firm believes Tesla's upcoming Powertrain Investor Day event in 2020 could shed light on Tesla's plans to scale production/capacity expansion, battery cost, chemistry, module and pack architecture, battery safety and durability, sourcing plans/collaboration by region and the role of the Maxwell acquisition.</li> <li>Credit Suisse keeps a price target of $200 on Tesla, but lifts its \"blue sky scenario\" price target to $400 from $365.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526522\" data-linked=\"Tesla rallies off praise from noted bear\" data-tweet=\"$TSLA - Tesla rallies off praise from noted bear https://seekingalpha.com/news/3526522-tesla-rallies-off-praise-from-noted-bear?source=tweet\" data-url=\"https://seekingalpha.com/news/3526522-tesla-rallies-off-praise-from-noted-bear\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>395&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526520\" data-ts=\"1576517083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCKT\" target=\"_blank\">RCKT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526520-rocket-pharma-up-10-on-prime-status-for-rp-l102-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rocket Pharma up 10% on PRIME status for RP-L102 in Europe</a></h4><ul><li>The European Medicines Agency has <a href=\"https://seekingalpha.com/pr/17728421-rocket-pharmaceuticals-receives-european-medicines-agency-prime-eligibility-for-rp-l102-gene\" target=\"_blank\">granted PRIME status</a> to Rocket Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/RCKT' title='Rocket Pharmaceuticals, Inc.'>RCKT</a> <font color=\"green\">+9.9%</font>) gene therapy RP-L102 for the treatment of a rare bone marrow failure called <a href=\"https://ghr.nlm.nih.gov/condition/fanconi-anemia\" target=\"_blank\">Fanconi anemia</a>.</li><li>PRIME, akin to Breakthrough Therapy status in the U.S., provides for more intensive guidance on development and accelerated review of the market application.</li><li>A Phase 2 study is in process.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526520\" data-linked=\"Rocket Pharma up 10% on PRIME status for RP-L102 in Europe\" data-tweet=\"$RCKT - Rocket Pharma up 10% on PRIME status for RP-L102 in Europe https://seekingalpha.com/news/3526520-rocket-pharma-up-10-on-prime-status-for-rp-l102-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3526520-rocket-pharma-up-10-on-prime-status-for-rp-l102-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526518\" data-ts=\"1576516695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEET\" target=\"_blank\">MEET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526518-meet-groupplus-5_7-on-acquisition-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Meet Group +5.7% on acquisition talks</a></h4><ul><li>The Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) gains as <a href=\"https://uk.reuters.com/article/uk-meet-group-m-a-prosieben-media-exclus/exclusive-prosiebens-nucom-eyes-acquisition-of-meet-group-sources-idUKKBN1YK1NP\" target=\"_blank\">Reuters sources</a> say Prosieben's NuCom is considering an acquisition.</li><li>NuCom, the owner of eharmony, has signaled its interest. Talks are in the early stages, and the deal could change or fail to happen.</li><li>MEET shares are <font color=\"green\">up 5.7%</font> to $5.35.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526518\" data-linked=\"Meet Group +5.7% on acquisition talks\" data-tweet=\"$MEET - Meet Group +5.7% on acquisition talks https://seekingalpha.com/news/3526518-meet-groupplus-5_7-on-acquisition-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3526518-meet-groupplus-5_7-on-acquisition-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526513\" data-ts=\"1576515755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526513-apple-gains-cleveland-sees-iphone-wearables-strength\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple gains as Cleveland sees iPhone, wearables strength</a></h4><ul><li>Cleveland Research says its checks show strong demand for Apple's (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+1.9%</font>) iPhones and wearables.</li><li>Analyst Ben Bollin: \"We have increased our revenue assumptions to reflect stronger momentum in iPhone, services, and other products and we continue to see potential for additional upside.\"</li><li>The supply chain reports that strong sales momentum continued into the holiday season. The mix of iPhones for newer products sustained at a higher mix, which has Cleveland \"feeling better\" about FY20 ASPs.</li><li>The firm has a Buy rating on Apple and expects shares to grow 15% by the end of FY21.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526513\" data-linked=\"Apple gains as Cleveland sees iPhone, wearables strength\" data-tweet=\"$AAPL - Apple gains as Cleveland sees iPhone, wearables strength https://seekingalpha.com/news/3526513-apple-gains-cleveland-sees-iphone-wearables-strength?source=tweet\" data-url=\"https://seekingalpha.com/news/3526513-apple-gains-cleveland-sees-iphone-wearables-strength\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526512\" data-ts=\"1576515699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526512-lear-and-pyxus-international-among-consumer-gainers-electrameccanica-vehicles-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lear and Pyxus International among consumer gainers; Electrameccanica Vehicles among losers</a></h4><ul><li><b>Gainers: </b>Bassett Furniture Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/BSET' title='Bassett Furniture Industries, Incorporated'>BSET</a>) <font color=\"green\">+13%</font>. Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"green\">+11%</font>. Lear (NYSE:<a href='https://seekingalpha.com/symbol/LEA' title='Lear Corporation'>LEA</a>) <font color=\"green\">+8%</font>. SunOpta (NASDAQ:<a href='https://seekingalpha.com/symbol/STKL' title='SunOpta Inc.'>STKL</a>) <font color=\"green\">+7%</font>. China Xiangtai Food (NASDAQ:<a href='https://seekingalpha.com/symbol/PLIN' title='China Xiangtai Food Co., Ltd.'>PLIN</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Kewaunee Scientific (NASDAQ:<a href='https://seekingalpha.com/symbol/KEQU' title='Kewaunee Scientific Corporation'>KEQU</a>) <font color=\"red\">-23%</font>. REV Group (NYSE:<a href='https://seekingalpha.com/symbol/REVG' title='REV Group, Inc.'>REVG</a>) <font color=\"red\">-8%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"red\">-7%</font>. Ballantyne Strong (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTN' title='Ballantyne Strong, Inc'>BTN</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526512\" data-linked=\"Lear and Pyxus International among consumer gainers; Electrameccanica Vehicles among losers\" data-tweet=\"$BSET $PYX $LEA - Lear and Pyxus International among consumer gainers; Electrameccanica Vehicles among losers https://seekingalpha.com/news/3526512-lear-and-pyxus-international-among-consumer-gainers-electrameccanica-vehicles-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526512-lear-and-pyxus-international-among-consumer-gainers-electrameccanica-vehicles-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526507\" data-ts=\"1576515387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCPH\" target=\"_blank\">DCPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526507-deciphera-files-u-s-application-for-ripretinib-for-gist\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deciphera files U.S. application for ripretinib for GIST</a></h4><ul><li>Deciphera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a> <font color=\"red\">-1%</font>) has <a href=\"https://seekingalpha.com/pr/17728436-deciphera-pharmaceuticals-announces-submission-of-new-drug-application-to-u-s-fda-for\" target=\"_blank\">submitted </a>a U.S. marketing application seeking approval for ripretinib for the treatment of patients with advanced gastrointestinal tumors &#40;GIST&#41; who have received prior treatment with imatinib, sunitinib and regorafenib, a Breakthrough Therapy and Orphan Drug indication.</li><li>Ripretinib is a tyrosine kinase switch control inhibitor engineered to broadly inhibit KIT- and PDGFRα-mutated kinases via a dual mechanism of action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526507\" data-linked=\"Deciphera files U.S. application for ripretinib for GIST\" data-tweet=\"$DCPH - Deciphera files U.S. application for ripretinib for GIST https://seekingalpha.com/news/3526507-deciphera-files-u-s-application-for-ripretinib-for-gist?source=tweet\" data-url=\"https://seekingalpha.com/news/3526507-deciphera-files-u-s-application-for-ripretinib-for-gist\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526504\" data-ts=\"1576514718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALK\" target=\"_blank\">ALK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526504-credit-suisse-boosts-price-target-on-alaska-air\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse boosts price target on Alaska Air</a></h4><ul> <li>Credit Suisse updates estimates on Alaska Air Group (<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a> <font color='green'>+1.6%</font>) in order to factor in today's <a href=\"https://seekingalpha.com/news/3526344-load-factor-falls-alaska-air\" target=\"_blank\">guidance update</a> from the airline operator.</li> <li>The firm expects 2019 EPS of  $6.37, 2020 EPS of $6.80 and 2021 EPS of $7.50 to reflect revised fuel price and efficiency assumptions.</li> <li>CS lifts its price target on Outperform-rated ALK to $82 vs. the <a href=\"https://seekingalpha.com/symbol/ALK/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $77.50.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3526504\" data-linked=\"Credit Suisse boosts price target on Alaska Air\" data-tweet=\"$ALK - Credit Suisse boosts price target on Alaska Air https://seekingalpha.com/news/3526504-credit-suisse-boosts-price-target-on-alaska-air?source=tweet\" data-url=\"https://seekingalpha.com/news/3526504-credit-suisse-boosts-price-target-on-alaska-air\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526501\" data-ts=\"1576514265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMRN\" target=\"_blank\">BMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526501-biomarins-vosoritide-successful-in-late-stage-achondroplasia-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioMarin&#39;s vosoritide successful in late-stage achondroplasia study</a></h4><ul><li>BioMarin Pharmaceutical (<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a> <font color=\"green\">+3.3%</font>) <a href=\"https://seekingalpha.com/pr/17728700-biomarin-announces-positive-final-results-from-placebo-controlled-phase-3-data-in-children\" target=\"_blank\">announces</a> positive results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03197766?cond=Achondroplasia&amp;lead=biomarin+pharmaceutical&amp;phase=2&amp;draw=2&amp;rank=2\" target=\"_blank\">Phase 3 clinical trial</a> evaluating vosoritide (BMN 111) in children with achondroplasia, a bone growth disorder characterized by dwarfism.</li><li>The study met the primary endpoint of a statistically significant change from baseline in mean annualized growth velocity at week 52 compared to placebo.</li><li>The company plans to meet with regulatory authorities in H1 2020 to clarify plans for marketing applications.</li><li><a href=\"https://www.biomarin.com/products/pipeline/bmn-111/\" target=\"_blank\">Vosoritide </a>is a stabilized version of C-type natriuretic peptide, a natural human peptide that is a positive regulator of bone growth.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526501\" data-linked=\"BioMarin&#39;s vosoritide successful in late-stage achondroplasia study\" data-tweet=\"$BMRN - BioMarin&#39;s vosoritide successful in late-stage achondroplasia study https://seekingalpha.com/news/3526501-biomarins-vosoritide-successful-in-late-stage-achondroplasia-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3526501-biomarins-vosoritide-successful-in-late-stage-achondroplasia-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526499\" data-ts=\"1576513217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XRF\" target=\"_blank\">XRF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526499-china-rapid-finance-may-bring-back-stock-buybacks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Rapid Finance may bring back stock buybacks</a></h4><ul><li>China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance Limited'>XRF</a>) <font color=\"green\">gains 2.7</font>% after announcing it <a href=\"https://seekingalpha.com/pr/17728542-china-rapid-finance-reports-2019-unaudited-financial-results-for-six-and-nine-months-ended\" target=\"_blank\">may reinstate</a> its stock buyback program after cost-cutting measures boosted its cash flow.</li><li>Earlier, XRF shares surged as much as 14%.</li><li>Cash and cash equivalents balance as of Sept. 30, 2019 were $15.5M, up from $12.5M at June 30, 2019.</li><li>For the nine months ended Sept. 30, 2019, net revenue fell to $23.5M from $48.2M in the year-ago period, reflecting the XRF exiting its legacy marketplace lending, as required by a change in China's regulatory policy.</li><li>Total operating expenses for the first three quarters of the fiscal year fell to $46.1M from $100.7M a year earlier.</li><li>Nine-month net loss of $22.8M, or 34 cents per share, narrowed from $51.8M, or 79 cents per share, a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526374-china-rapid-finance-reports-9m-results\" target=\"_blank\">China Rapid Finance reports 9M results</a> (Dec. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526499\" data-linked=\"China Rapid Finance may bring back stock buybacks\" data-tweet=\"$XRF - China Rapid Finance may bring back stock buybacks https://seekingalpha.com/news/3526499-china-rapid-finance-may-bring-back-stock-buybacks?source=tweet\" data-url=\"https://seekingalpha.com/news/3526499-china-rapid-finance-may-bring-back-stock-buybacks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526498\" data-ts=\"1576513164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRNA\" target=\"_blank\">DRNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526498-alexion-nabs-rights-to-two-new-programs-from-dicerna\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion nabs rights to two new programs from Dicerna</a></h4><ul><li>Dicerna Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color=\"green\">+1.6%</font>) and collaboration partner Alexion Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color=\"green\">+0.8%</font>) <a href=\"https://seekingalpha.com/pr/17728593-alexion-exercises-option-for-two-additional-galxc-rnai-programs-for-complement-mediated\" target=\"_blank\">announce </a>that the latter has exercised its option for exclusive rights to two additional GalXC RNAi targets within the complement pathway, increasing the number of programs to four.</li><li>Alexion will pay Dicerna $20M for the two licenses.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526498\" data-linked=\"Alexion nabs rights to two new programs from Dicerna\" data-tweet=\"$DRNA $ALXN - Alexion nabs rights to two new programs from Dicerna https://seekingalpha.com/news/3526498-alexion-nabs-rights-to-two-new-programs-from-dicerna?source=tweet\" data-url=\"https://seekingalpha.com/news/3526498-alexion-nabs-rights-to-two-new-programs-from-dicerna\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526497\" data-ts=\"1576513094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFN\" target=\"_blank\">INFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526497-infineraplus-5_9-after-needham-target-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinera +5.9% after Needham target boost</a></h4><ul><li>Needham raises its Infinera (NASDAQ:<a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a>) target from $9 to $10, citing reports that the company has started showing off its 800G DSP.</li><li>Analyst Alex Henderson calls this \"really good news\" because INFN wouldn't demo a product \"if they hadn't had highly successful results in their internal testing.\"</li><li>Henderson maintains a Strong Buy rating on the company. INFN has a Bullish average <a href=\"https://seekingalpha.com/symbol/INFN/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Infinera shares are <font color=\"green\">up 5.9%</font> to $7.36.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526497\" data-linked=\"Infinera +5.9% after Needham target boost\" data-tweet=\"$INFN - Infinera +5.9% after Needham target boost https://seekingalpha.com/news/3526497-infineraplus-5_9-after-needham-target-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3526497-infineraplus-5_9-after-needham-target-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526494\" data-ts=\"1576512646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MIRM\" target=\"_blank\">MIRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526494-mirum-pharma-up-123-on-advancement-of-lead-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mirum Pharma up 123% on advancement of lead candidate</a></h4><ul><li>Thinly traded Mirum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/MIRM' title='Mirum Pharmaceuticals, Inc.'>MIRM</a> <font color=\"green\">+122.6%</font>) jumps on a whopping 104x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/17728619-mirum-pharmaceuticals-completes-successful-pre-nda-meeting-fda-for-maralixibat\" target=\"_blank\">advancement </a>of lead drug maralixibat for the treatment of pruritis (itchy skin) associated with a rare inherited bile duct disorder (ducts are abnormally narrow) called <a href=\"https://ghr.nlm.nih.gov/condition/alagille-syndrome#statistics\" target=\"_blank\">Alagille syndrome</a>, a Breakthrough Therapy and Rare Pediatric Disease-designated indication.</li><li>The company recently completed a pre-NDA meeting with the FDA clarifying the required contents of its rolling marketing application, expected to commence in Q3 2020.</li><li>Results from a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02160782?lead=mirum+pharmaceuticals&amp;phase=1&amp;draw=2&amp;rank=4\" target=\"_blank\">ICONIC</a>, showed statistically significant reductions from baseline in serum bile acid and pruritis at weeks 18 and 48 versus placebo. The treatment benefits were sustained through 191 weeks in an <a href=\"https://clinicaltrials.gov/ct2/show/NCT02117713?lead=mirum+pharmaceuticals&amp;phase=1&amp;draw=2&amp;rank=5\" target=\"_blank\">extension study</a>.</li><li><a href=\"https://mirumpharma.com/programs/#section_maralixibat\" target=\"_blank\">Maralixibat </a>is an orally available inhibitor of a protein called <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796132/\" target=\"_blank\">the apical sodium-dependent bile acid transporter</a> which increases the amount of bile acid excreted in the feces thereby lowering bile acid levels in the body.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526494\" data-linked=\"Mirum Pharma up 123% on advancement of lead candidate\" data-tweet=\"$MIRM - Mirum Pharma up 123% on advancement of lead candidate https://seekingalpha.com/news/3526494-mirum-pharma-up-123-on-advancement-of-lead-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3526494-mirum-pharma-up-123-on-advancement-of-lead-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526488\" data-ts=\"1576512229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526488-healthcare-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Mirum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MIRM' title='Mirum Pharmaceuticals, Inc.'>MIRM</a>) <font color=\"green\">+122%</font>. Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+70%</font>. BioXcel Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BTAI' title='BioXcel Therapeutics, Inc.'>BTAI</a>) <font color=\"green\">+21%</font>. Relmada Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RLMD' title='Relmada Therapeutics, Inc.'>RLMD</a>) <font color=\"green\">+17%</font>. La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Company'>LJPC</a>) <font color=\"green\">+14%</font>.</li><li><b>Losers: </b>Wave Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/WVE' title='Wave Life Sciences Ltd.'>WVE</a>) <font color=\"red\">-52%</font>. Gossamer Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/GOSS' title='Gossamer Bio, Inc.'>GOSS</a>) <font color=\"red\">-36%</font>. NantKwest (NASDAQ:<a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a>) <font color=\"red\">-18%</font>. Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) <font color=\"red\">-14%</font>. Forward Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/FWP' title='Forward Pharma A/S'>FWP</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526488\" data-linked=\"Healthcare - Top 5 Gainers / Losers\" data-tweet=\"$MIRM $AXSM $BTAI - Healthcare - Top 5 Gainers / Losers https://seekingalpha.com/news/3526488-healthcare-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526488-healthcare-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526478\" data-ts=\"1576511229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526478-airline-stocks-bid-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airline stocks bid up</a></h4><ul> <li>Airline stocks are outperforming the broad market today as sentiment has swung positive following last week's trade developments and Delta's <a href=\"https://seekingalpha.com/news/3525828-delta-air-linesplus-2-after-guidance-boost\" target=\"_blank\">guidance update</a>.</li>  <li>Gainers include Spirit Airlines (NYSE:<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines, Inc.'>SAVE</a>) <font color=\"green\">+3.38%</font>, American Airlines Group (NASDAQ:<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group Inc.'>AAL</a>) <font color=\"green\">+2.24%</font>, Alaska Air Group (NYSE:<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a>) <font color=\"green\">+1.91%</font>, Delta Air Lines (NYSE:<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a>) <font color=\"green\">+1.86%</font>, United Airlines (NASDAQ:<a href='https://seekingalpha.com/symbol/UAL' title='United Airlines Holdings, Inc.'>UAL</a>) <font color=\"green\">+1.77%</font>, SkyWest (NASDAQ:<a href='https://seekingalpha.com/symbol/SKYW' title='SkyWest, Inc.'>SKYW</a>) <font color=\"green\">+1.44%</font> and JetBlue (NASDAQ:<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a>) <font color=\"green\">+1.40%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526478\" data-linked=\"Airline stocks bid up\" data-tweet=\"$SAVE $AAL $ALK - Airline stocks bid up https://seekingalpha.com/news/3526478-airline-stocks-bid-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3526478-airline-stocks-bid-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526472\" data-ts=\"1576510473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUI\" target=\"_blank\">SUI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526472-sun-communities-convertsminus-4-preferred-common-stock-units\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sun Communities converts A-4 preferred into common stock, units</a></h4><ul><li>Sun Communities (NYSE:<a href='https://seekingalpha.com/symbol/SUI' title='Sun Communities, Inc.'>SUI</a>)<font color=\"red\"> slips 0.9% </font>after<a href=\"https://seekingalpha.com/pr/17728952-sun-communities-inc-announces-conversion-of-all-seriesminus-4-securities\" target=\"_blank\"> converting </a>all of its series A-4 preferred securities into common stock and operating partnership units.</li><li>On Dec. 13, 2019, ~1.03M shares of series A-4 preferred stock were converted into 458,554 shares of common stock and 405,656 of series A-4 preferred OP units were converted into 180,291 common OP units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526472\" data-linked=\"Sun Communities converts A-4 preferred into common stock, units\" data-tweet=\"$SUI - Sun Communities converts A-4 preferred into common stock, units https://seekingalpha.com/news/3526472-sun-communities-convertsminus-4-preferred-common-stock-units?source=tweet\" data-url=\"https://seekingalpha.com/news/3526472-sun-communities-convertsminus-4-preferred-common-stock-units\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526465\" data-ts=\"1576509240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526465-amgen-prevails-in-epogen-patent-dispute-hospira\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amgen prevails in Epogen patent dispute with Hospira</a></h4><ul><li>An appeals court has affirmed a lower court verdict that Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"green\">+2.7%</font>) unit Hospira's proposed Epogen biosimilar infringes on Amgen's (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"green\">+2.3%</font>) U.S. Patent No. 5,856,298, upholding $70M in damages <a href=\"https://www.centerforbiosimilars.com/news/hospira-ordered-to-pay-amgen-70-million-over-epoetin-alfa-patent-infringement\" target=\"_blank\">awarded </a>in September 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526465\" data-linked=\"Amgen prevails in Epogen patent dispute with Hospira\" data-tweet=\"$PFE $AMGN - Amgen prevails in Epogen patent dispute with Hospira https://seekingalpha.com/news/3526465-amgen-prevails-in-epogen-patent-dispute-hospira?source=tweet\" data-url=\"https://seekingalpha.com/news/3526465-amgen-prevails-in-epogen-patent-dispute-hospira\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526463\" data-ts=\"1576508956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REVG\" target=\"_blank\">REVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526463-rev-groupminus-14-after-morgan-stanley-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rev Group -14% after Morgan Stanley cut</a></h4><ul> <li>Rev Group (NYSE:<a href='https://seekingalpha.com/symbol/REVG' title='REV Group, Inc.'>REVG</a>) falls sharply after Morgan Stanley lowers its rating to Underweight from Equal-weight.</li> <li>The firm warns that consensus earnings estimates on Rev Group could be too high with the RV market still facing pressure.</li> <li>Shares of Rev Group are <font color=\"red\">down 14.33%</font> to trade at their lowest level since October on a day that peers are all showing gains.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526463\" data-linked=\"Rev Group -14% after Morgan Stanley cut\" data-tweet=\"$REVG - Rev Group -14% after Morgan Stanley cut https://seekingalpha.com/news/3526463-rev-groupminus-14-after-morgan-stanley-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3526463-rev-groupminus-14-after-morgan-stanley-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526457\" data-ts=\"1576508614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRD\" target=\"_blank\">TLRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526457-michael-burry-pressures-tailored-brands-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Michael Burry pressures Tailored Brands again</a></h4><ul> <li>Scion Asset Management discloses that it increased its stake in Tailored Brands (<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a> <font color='red'>-0.7%</font>) to 6.4% from 5.7% prior.</li> <li>Michael Burry's firm says it continues to engage with Tailored Brands management and has issued specific recommendations on costs, debt reduction strategies and leaseback transactions.</li> <li>Shares of TLRD are down 70% YTD.</li> <li><a href=\"https://www.sec.gov/Archives/edgar/data/884217/000114036119022529/efc19-736_sc13da.htm\" target=\"_blank\">SEC Form 13D</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3526457\" data-linked=\"Michael Burry pressures Tailored Brands again\" data-tweet=\"$TLRD - Michael Burry pressures Tailored Brands again https://seekingalpha.com/news/3526457-michael-burry-pressures-tailored-brands-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3526457-michael-burry-pressures-tailored-brands-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526449\" data-ts=\"1576508036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526449-urban-outfitters-slips-after-loop-capital-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters slips after Loop Capital cut</a></h4><ul> <li>Loop Capital singles out Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='red'>-1.1%</font>) for being at risk of heightened promotional activity clipping profit.</li> <li>\"We believe promotional activity has intensified more than usual among specialty apparel retailers, and F2020 EPS estimates have not been lowered enough in our view. Our F2020 EPS estimate of $2.10 is 28 cents below consensus, with SSS modeled +4.2%. Consensus SSS is projected at +2.9%, but gross margin consensus is 80 bps above our projection,\" <a href=\"https://www.cnbc.com/2019/12/16/analyst-calls-of-the-day-on-monday-micron-western-digital-more.html\" target=\"_blank\">notes</a> the Loop analyst team.</li> <li>Pricing is not just an issue at Urban Outfitters as the consumer price report last week indicated a significant <a href=\"https://seekingalpha.com/news/3525492-markdown-madness-in-retail\" target=\"_blank\">drop</a> in apparel prices across the sector during November. However, URBN has been targeted by several firms as one of the retailers being pinched the most.</li><li>Loop Capital drops Urban Outfitters to a Hold rating from Buy.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526449\" data-linked=\"Urban Outfitters slips after Loop Capital cut\" data-tweet=\"$URBN - Urban Outfitters slips after Loop Capital cut https://seekingalpha.com/news/3526449-urban-outfitters-slips-after-loop-capital-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3526449-urban-outfitters-slips-after-loop-capital-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526446\" data-ts=\"1576507947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526446-stocks-open-higher-paced-and-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks open higher, paced by IT and energy</a></h4><ul><li>U.S. stocks advance in early trading, with the S&amp;P 500 hitting an all-time high, as IT and energy outpace the broader market.</li><li>With nerves over U.S.-China trade negotiations calmed by a Phase One pact announced last week, investors feel more confident; strong economic data out of China also helped as industrial rose 6.2% in November Y/Y and retail sales improved 8%.</li><li>The S&amp;P 500 touched 3,192.91, surpassing its previous record high of 3,182.67 reached in the previous session.</li><li>S&amp;P is <font color=\"green\">up 0.8%</font>, the Nasdaq <font color=\"green\">gains 0.7%</font>, and the Dow <font color=\"green\">adds 0.5%</font>.</li><li>10-year Treasury falls, pushing yield up 3 basis points to 1.86%.</li><li>Among notable movers, Intel <font color=\"green\">gains 1.1%</font> after acquiring Habana Labs, an AI chipmaker, Apple <font color=\"green\">advances 1.1%</font> after an Evercore survey shows its products dominate holiday wish lists, and Goldman Sachs <font color=\"green\">jumps 2.3%</font> after Citi upgrades the stock, and</li><li>Boeing slides 3.1% after reports that the planemaker could either suspend or cut back production on the 737 MAX after failing to meet its own deadline for FAA recertification of the grounded jet.</li><li>Crude oil edges up 0.2% to $60.19 per barrel.</li><li>An early glance at the S&amp;P 500 industry sectors shows information technology  (+1.0%) and energy (+1.0%) gaining the most and real estate (flat) and utilities (+0.2%) lagging the broader market.</li><li>Dollar Index falls 0.2% to 96.99.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526446\" data-linked=\"Stocks open higher, paced by IT and energy\" data-tweet=\"Stocks open higher, paced by IT and energy https://seekingalpha.com/news/3526446-stocks-open-higher-paced-and-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3526446-stocks-open-higher-paced-and-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526444\" data-ts=\"1576507805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526444-supreme-court-wont-hear-dish-robocall-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supreme Court won&#39;t hear DISH robocall case</a></h4><ul><li>The U.S. Supreme Court <a href=\"https://news.bloomberglaw.com/class-action/dish-network-denied-high-court-eye-on-no-injury-robocall-case\" target=\"_blank\">won't review</a> the class action judgment against Dish Network (NASDAQ:<a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a>) for robocalls to numbers on the Do Not Call list.</li><li>The Court leaves intact the Fourth Circuit\u2019s ruling affirming the jury award of $61M.</li><li>The jury had found that Dish violated the Telephone Consumer Protection Act. Dish argued the people didn't have the legal right to sue because they weren't injured.</li><li>DISH shares are <font color=\"green\">up 1.6%</font> to $34.67.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526444\" data-linked=\"Supreme Court won&#39;t hear DISH robocall case\" data-tweet=\"$DISH - Supreme Court won&#39;t hear DISH robocall case https://seekingalpha.com/news/3526444-supreme-court-wont-hear-dish-robocall-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3526444-supreme-court-wont-hear-dish-robocall-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526440\" data-ts=\"1576507531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLOG\" target=\"_blank\">GLOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526440-gaslog-announces-newbuild-financing-facility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GasLog announces Newbuild financing facility</a></h4><ul><li>GasLog (<a href='https://seekingalpha.com/symbol/GLOG' title='GasLog Ltd.'>GLOG</a> <font color=\"green\">+4%</font>) <a href=\"https://seekingalpha.com/pr/17728479-gaslog-ltd-announces-newbuild-financing-facility-enhancements-to-existing-facilities-and\" target=\"_blank\">signs</a> an Export Credit Agency-backed debt financing of $1.05B with twelve international banks for its current newbuilding program (Newbuild Facility).</li><li>Newbuild Facility covers the balance due to the shipyard on delivery and consequently the final instalments of the seven newbuildings are fully funded.</li><li>GasLog also amended the covenants on its existing bank facilities to align them with the terms of the Newbuild Facility and the recently concluded GasLog Warsaw facility.</li><li>In addition, GasLog has called the remaining NOK 434M of its 2021 NOK Bond, that will be settled in January 2020 with proceeds from its 2024 NOK 900M bond issued November 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526440\" data-linked=\"GasLog announces Newbuild financing facility\" data-tweet=\"$GLOG - GasLog announces Newbuild financing facility https://seekingalpha.com/news/3526440-gaslog-announces-newbuild-financing-facility?source=tweet\" data-url=\"https://seekingalpha.com/news/3526440-gaslog-announces-newbuild-financing-facility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526439\" data-ts=\"1576507489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPB\" target=\"_blank\">SPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526439-spectrum-brands-rallies-after-oppenheimer-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum Brands rallies after Oppenheimer upgrade</a></h4><ul> <li>Oppenheimer lifts its rating on Spectrum Brands (<a href='https://seekingalpha.com/symbol/SPB' title='Spectrum Brands Holdings, Inc.'>SPB</a> <font color='green'>+4.1%</font>) on its view that all four of the company's business units should grow in FY20.</li> <li>\"Pet has the most momentum and margin potential. In FY20, HPC comparisons ease, and H&amp;G has favorable weather comps. HHI should also grow, despite a housing moderation,\" writes analyst Ian Zaffino.</li> <li>The firm moves to an Outperform rating on SPB from Perfom and assigns a price target of $80 based on a sum-of-the-parts analysis.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526439\" data-linked=\"Spectrum Brands rallies after Oppenheimer upgrade\" data-tweet=\"$SPB - Spectrum Brands rallies after Oppenheimer upgrade https://seekingalpha.com/news/3526439-spectrum-brands-rallies-after-oppenheimer-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3526439-spectrum-brands-rallies-after-oppenheimer-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526436\" data-ts=\"1576507434\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVDL\" target=\"_blank\">AVDL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526436-fda-oks-avadels-nouress-shares-down-17-on-launch-uncertainty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Avadel&#39;s Nouress; shares down 17% on launch uncertainty</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17728667-avadel-pharmaceuticals-receives-u-s-fda-approval-for-nouress-av001-cysteine-hydrochloride\" target=\"_blank\">approves </a>Avadel Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/AVDL' title='Avadel Pharmaceuticals plc'>AVDL</a> <font color=\"red\">-16.8%</font>) Nouress (cysteine hydrochloride injection) (AV001) for neonates requiring <a href=\"https://medlineplus.gov/ency/patientinstructions/000177.htm\" target=\"_blank\">total parenteral nutrition</a> &#40;TPN&#41; (method of feeding that bypasses the GI tract).</li><li>The company says the U.S. market could be greater than $50M.</li><li>On another note, the USPTO recently issued a new patent to the company covering cysteine solutions, including Nouress.</li><li>Investors appear to be reacting to its statement that it is \"evaluating\" the timing and process for commercial launch, adding that a competitor's product (Exela Pharma Service's Elcys <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210660Orig1s000ltr.pdf\" target=\"_blank\">approved </a>in April) was approved in the U.S. earlier this year and has also received a U.S. patent.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526436\" data-linked=\"FDA OKs Avadel&#39;s Nouress; shares down 17% on launch uncertainty\" data-tweet=\"$AVDL - FDA OKs Avadel&#39;s Nouress; shares down 17% on launch uncertainty https://seekingalpha.com/news/3526436-fda-oks-avadels-nouress-shares-down-17-on-launch-uncertainty?source=tweet\" data-url=\"https://seekingalpha.com/news/3526436-fda-oks-avadels-nouress-shares-down-17-on-launch-uncertainty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526433\" data-ts=\"1576506629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526433-wve-goss-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WVE, GOSS among premarket losers</a></h4><ul><li>Wave Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/WVE' title='Wave Life Sciences Ltd.'>WVE</a>) <font color=\"red\">-52%</font> on <a href=\"https://seekingalpha.com/news/3526368-wave-craters-59-premarket-on-exit-from-dmd\" target=\"_blank\">exit</a> from DMD.</li><li>Gossamer Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/GOSS' title='Gossamer Bio, Inc.'>GOSS</a>) <font color=\"red\">-31%</font> after Novartis to <a href=\"https://seekingalpha.com/news/3526363-novartis-exit-from-fevipiprant-pressures-gossamer-bio-down-38-premarket\" target=\"_blank\">terminate</a> fevipiprant.</li><li>Pacific Gas &amp; Electric (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"red\">-21%</font> California Governor Gavin Newsom <a href=\"https://seekingalpha.com/news/3526308-newsom-rejects-pg-and-e-bankruptcy-plan\" target=\"_blank\">rejects</a> bankruptcy plan.</li><li>Nantkwest (NASDAQ:<a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a>) <font color=\"red\">-10%</font> on NK cell combo <a href=\"https://seekingalpha.com/news/3526423-nantkwest-down-8-premarket-on-nk-cell-combo-data-in-tnbc\" target=\"_blank\">data</a> in TNBC.</li><li>International Flavors &amp; Fragrances (NYSE:<a href='https://seekingalpha.com/symbol/IFF' title='International Flavors & Fragrances Inc.'>IFF</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3526321-dupont-nutrition-unit-to-merge-iff\" target=\"_blank\">merger</a> with DuPont nutrition unit.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526433\" data-linked=\"WVE, GOSS among premarket losers\" data-tweet=\"$WVE $GOSS $PCG - WVE, GOSS among premarket losers https://seekingalpha.com/news/3526433-wve-goss-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526433-wve-goss-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526432\" data-ts=\"1576506523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526432-goldman-sachs-moves-up-1_5-after-citi-turns-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs moves up 1.5% after Citi turns bullish</a></h4><ul><li>Goldman Sachs Group (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='The Goldman Sachs Group, Inc.'>GS</a>)<font color=\"green\"> gains 1.5%</font> in premarket trading after Citi analyst Keith Horowitz <a href=\"https://twitter.com/OpenOutcrier/status/1206575381928665088\" target=\"_blank\">upgrades the stock</a> to buy from neutral.</li><li>Raises price target to $255 from $220.</li><li>Compares with <a href=\"https://seekingalpha.com/symbol/GS/ratings/quant-ratings\" target=\"_blank\">Quant rating</a> of Neutral; before this action, <a href=\"https://seekingalpha.com/symbol/GS/ratings/sell-side-ratings\" target=\"_blank\">Sell-Side average rating </a>was Neutral (6 Very Bullish, 4 Bullish, 16 Neutral, 1 Bearish, 1 Very Bearish).</li></ul><div class=\"tiny-share-widget\" data-id=\"3526432\" data-linked=\"Goldman Sachs moves up 1.5% after Citi turns bullish\" data-tweet=\"$GS - Goldman Sachs moves up 1.5% after Citi turns bullish https://seekingalpha.com/news/3526432-goldman-sachs-moves-up-1_5-after-citi-turns-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/3526432-goldman-sachs-moves-up-1_5-after-citi-turns-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526429\" data-ts=\"1576506368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526429-axsm-slrx-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AXSM, SLRX among premarket gainers</a></h4><ul><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+82%</font> on <a href=\"https://seekingalpha.com/news/3526334-axsomeplus-56-premarket-on-positive-axsminus-05-data-in-mdd\" target=\"_blank\">positive</a> AXS-05 data in MDD.</li><li>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+22%</font>.</li><li>Salarius Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SLRX' title='Salarius Pharmaceuticals, Inc.'>SLRX</a>) <font color=\"green\">+15%</font> on receiving <a href=\"https://seekingalpha.com/pr/17728665-salarius-pharmaceuticals-receives-fda-fast-track-designation-for-lead-drug-candidate\" target=\"_blank\">Fast Track Designation</a> for Seclidemstat.</li><li>Finvolution Group (NYSE:<a href='https://seekingalpha.com/symbol/FINV' title='FinVolution Group'>FINV</a>) <font color=\"green\">+6%</font> on announcing <a href=\"https://seekingalpha.com/pr/17728299-finvolution-group-announces-strategic-investment-and-partnership-fujian-haixia-bank\" target=\"_blank\">partnership</a> with Fujian Haixia Bank.</li><li>Owens &amp; Minor (NYSE:<a href='https://seekingalpha.com/symbol/OMI' title='Owens & Minor, Inc.'>OMI</a>) <font color=\"green\">+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526429\" data-linked=\"AXSM, SLRX among premarket gainers\" data-tweet=\"$AXSM $CEI $SLRX - AXSM, SLRX among premarket gainers https://seekingalpha.com/news/3526429-axsm-slrx-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526429-axsm-slrx-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526428\" data-ts=\"1576506261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLRX\" target=\"_blank\">SLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526428-salarius-pharmas-seclidemstat-fast-trackd-for-ewing-sarcoma-shares-up-12-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Salarius Pharma&#39;s seclidemstat Fast Track&#39;d for Ewing sarcoma; shares up 12% PM</a></h4><ul><li>Thinly traded nano cap Salarius Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SLRX' title='Salarius Pharmaceuticals, Inc.'>SLRX</a>) is up <font color=\"green\">12%</font> premarket on increased volume in reaction to <a href=\"https://seekingalpha.com/pr/17728665-salarius-pharmaceuticals-receives-fda-fast-track-designation-for-lead-drug-candidate\" target=\"_blank\">Fast Track designation</a> in the U.S. for lead candidate seclidemstat for the treatment of a rare pediatric bone cancer called Ewing sarcoma.</li><li>Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li><li>Phase 1-stage <a href=\"http://salariuspharma.com/our-programs/pipeline/\" target=\"_blank\">seclidemstat </a>is a small molecule inhibitor of an epigenetic enzyme called lysine-specific demethylase 1 (LSD1), highly expressed in certain cancers and associated with aggressive disease and poor prognosis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526428\" data-linked=\"Salarius Pharma&#39;s seclidemstat Fast Track&#39;d for Ewing sarcoma; shares up 12% PM\" data-tweet=\"$SLRX - Salarius Pharma&#39;s seclidemstat Fast Track&#39;d for Ewing sarcoma; shares up 12% PM https://seekingalpha.com/news/3526428-salarius-pharmas-seclidemstat-fast-trackd-for-ewing-sarcoma-shares-up-12-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3526428-salarius-pharmas-seclidemstat-fast-trackd-for-ewing-sarcoma-shares-up-12-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526424\" data-ts=\"1576505874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526424-intel-acquires-ai-chipmaker-for-2b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel acquires AI chipmaker for $2B</a></h4><ul><li>Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) announces <a href=\"https://seekingalpha.com/pr/17728849-intel-acquires-artificial-intelligence-chipmaker-habana-labs\" target=\"_blank\">acquiring</a> Habana Labs for about $2B.</li><li>The Israel-based company develops programmable deep learning accelerators for data centers.</li><li>Intel says the purchase helps bolster its AI strategy. INTC expects to generate over $3.5B in AI-driven revenue in 2019, up 20% Y/Y.</li><li>Habana will remain an independent unit under the current management team and will report to Intel's Data Platforms Group.</li><li>Related: Earlier this month, Globes <a href=\"https://seekingalpha.com/news/3523285-intel-in-talks-for-israeli-chip-company-report\" target=\"_blank\">reported</a> that Intel was in advanced talks to acquire Habana.</li><li>Intel shares are <font color=\"green\">up 0.9%</font> pre-market to $58.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526424\" data-linked=\"Intel acquires AI chipmaker for $2B\" data-tweet=\"$INTC - Intel acquires AI chipmaker for $2B https://seekingalpha.com/news/3526424-intel-acquires-ai-chipmaker-for-2b?source=tweet\" data-url=\"https://seekingalpha.com/news/3526424-intel-acquires-ai-chipmaker-for-2b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526423\" data-ts=\"1576505799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NK\" target=\"_blank\">NK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526423-nantkwest-down-8-premarket-on-nk-cell-combo-data-in-tnbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NantKwest down 8% premarket on NK cell combo data in TNBC</a></h4><ul><li>NantKwest (NASDAQ:<a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a>) <a href=\"https://seekingalpha.com/pr/17728424-nantkwest-and-immunitybio-present-results-of-landmark-trial-of-first-in-human-natural-killer\" target=\"_blank\">announces </a>positive results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03387085?lead=nantkwest&amp;phase=0&amp;draw=2&amp;rank=11\" target=\"_blank\">Phase 1b clinical trial</a> evaluating the combination of its antibody-targeted NK cells, ImmunityBio's N-803 (an IL-15 superagonist), low-dose chemo, adenoviral and yeast tumor-associated antigen vaccines (MUC1, brachyury, CEA) and a PD-L1 checkpoint inhibitor in patients with triple negative breast cancer &#40;TNBC&#41; who relapsed after prior treatment. The results were presented at the San Antonio Breast Cancer Symposium.</li><li>The overall response rate &#40;ORR&#41; in nine participants was 67% (n=6/9), including two complete responders. One patient experienced stable cancer implying a disease control rate of 78% (n=7/9). Durations of response ranged from 2-12 months. Median progression-free survival &#40;PFS&#41; was 13.7 months. Four patients remain on study.</li><li>On the safety front, all subjects experienced at least one serious treatment-emergent adverse event, most being chemo-related neutropenia or anemia. Serious (or greater) haNK-related adverse events occurred in two patients (fever and fatigue).</li><li>Development is ongoing.</li><li>Shares down <font color=\"red\">8%</font> premarket on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526423\" data-linked=\"NantKwest down 8% premarket on NK cell combo data in TNBC\" data-tweet=\"$NK - NantKwest down 8% premarket on NK cell combo data in TNBC https://seekingalpha.com/news/3526423-nantkwest-down-8-premarket-on-nk-cell-combo-data-in-tnbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3526423-nantkwest-down-8-premarket-on-nk-cell-combo-data-in-tnbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526420\" data-ts=\"1576505265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNX\" target=\"_blank\">ATNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526420-athenex-expands-strategic-partnership-xiangxue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athenex expands its strategic partnership with Xiangxue</a></h4><ul> <li>Athenex (NASDAQ:<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a>) has <a href=\"https://seekingalpha.com/pr/17728485-athenex-expands-strategic-partnership-guangzhou-xiangxue-pharmaceutical-through-licensing\" target=\"_blank\">expanded</a> its strategic partnership with Chinese drug company, Guangzhou Xiangxue Pharmaceutical Co., Ltd., to exclusively develop and commercialize Athenex\u2019s Oral Paclitaxel (both the capsule and the tablet formulations), Oral Irinotecan, as well as Tirbanibulin (KX2-391, also known as KX-01) Ointment, including for the treatment of actinic keratosis &#40;AK&#41; in China, Hong Kong and Macao (\"the Territory\").</li>  <li>Under the terms of the license agreement, Athenex will receive an upfront payment of $30M, milestone payments up to $170M, and tiered royalties ranging from sub-teen to low twenties.</li>  <li>Athenex will look after global drug development efforts while Xiangxue will oversee commercialization activities in the Territory.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3526420\" data-linked=\"Athenex expands its strategic partnership with Xiangxue\" data-tweet=\"$ATNX - Athenex expands its strategic partnership with Xiangxue https://seekingalpha.com/news/3526420-athenex-expands-strategic-partnership-xiangxue?source=tweet\" data-url=\"https://seekingalpha.com/news/3526420-athenex-expands-strategic-partnership-xiangxue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526416\" data-ts=\"1576505035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WW\" target=\"_blank\">WW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526416-ww-internationalplus-5-on-oprah-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WW International +5% on Oprah confidence</a></h4><ul> <li>WW International (NASDAQ:<a href='https://seekingalpha.com/symbol/WW' title='WW International, Inc.'>WW</a>) jumps in early trading after Oprah Winfrey <a href=\"https://seekingalpha.com/pr/17728752-ww-and-oprah-winfrey-announce-extension-of-partnership-2025\" target=\"_blank\">extends</a> a partnership with the company until 2025 and says she plans to stay on the board.</li> <li>\"I believe in WW\u2019s mission and the power of its program to create positive, lasting change for everyone who wants a partner to help support them in pursuing a stronger, healthier life,\" notes Winfrey.</li> <li>Winfrey was also granted a fully vested option to purchase ~3.3M shares of WW following shareholder approval. After factoring in the options and a stock trading plan, Winfrey would own ~2.5M shares of WW and options with respect to 4.0M shares.</li> <li>Shares of WW International are <font color=\"green\">up 5.35%</font> premarket to $39.99 vs. the 52-week trading range of $16.71 to $49.04.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526416\" data-linked=\"WW International +5% on Oprah confidence\" data-tweet=\"$WW - WW International +5% on Oprah confidence https://seekingalpha.com/news/3526416-ww-internationalplus-5-on-oprah-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3526416-ww-internationalplus-5-on-oprah-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526415\" data-ts=\"1576504976\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACAD\" target=\"_blank\">ACAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526415-acadia-pharma-gets-new-bull-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acadia Pharma gets a new bull - shares up 2%</a></h4><ul><li>Nuplazid is on track to become the established standard of care in Parkinson\u2019s disease psychosis &#40;PDP&#41;, says Guggenheim's Yatin Suneja, initiating Acadia Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a>) with a Buy rating and $60 price target (<font color=\"green\">36% upside</font> from last week's close).</li><li>Then there's the drug's approval and launch for dementia-related psychosis &#40;DRP&#41;, which is 10x the size of PDP.</li><li>Suneja is also a fan of the company's pipeline beyond those two treatments.</li><li>The <a href=\"https://seekingalpha.com/symbol/ACAD/ratings/sell-side-ratings\" target=\"_blank\">average Sell-Side rating</a> on ACAD is bullish, and the <a href=\"https://seekingalpha.com/symbol/ACAD/ratings/author-ratings\" target=\"_blank\">average SA Author rating</a> is very bullish.</li><li>Shares are<font color=\"green\"> up 1.95%</font> premarket to $45.20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526415\" data-linked=\"Acadia Pharma gets a new bull - shares up 2%\" data-tweet=\"$ACAD - Acadia Pharma gets a new bull - shares up 2% https://seekingalpha.com/news/3526415-acadia-pharma-gets-new-bull-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3526415-acadia-pharma-gets-new-bull-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526409\" data-ts=\"1576504488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGNE\" target=\"_blank\">BGNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526409-beigenes-zanubrutinib-fails-to-beat-imbruvica-in-wm-study-shares-down-9-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BeiGene&#39;s zanubrutinib fails to beat Imbruvica in WM study; shares down 9% PM</a></h4><ul><li>BeiGene (NASDAQ:<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene, Ltd.'>BGNE</a>) is down <font color=\"red\">9%</font> premarket on modest volume in reaction to <a href=\"https://seekingalpha.com/pr/17728481-beigene-announces-results-of-phase-3-aspen-trial-of-zanubrutinib-compared-to-ibrutinib-for\" target=\"_blank\">results </a>from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03053440?titles=aspen&amp;lead=beigene&amp;draw=2&amp;rank=1\" target=\"_blank\">ASPEN</a>, comparing BTK inhibitor Brukinsa (zanubrutinib) to AbbVie's (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) Imbruvica (ibrutinib) in patients with a type of lymphoma called <a href=\"https://rarediseases.org/rare-diseases/waldenstroms-macroglobulinemia/\" target=\"_blank\">Waldenström\u2019s macroglobulinemia</a> &#40;WM&#41;.</li><li>The study failed to achieve the primary endpoint of demonstrating zanubrutinib's superiority to ibrutinib as measured by the proportion of patients experiencing either a complete response &#40;CR&#41; or very good partial response &#40;VGPR&#41; in up to three years.</li><li>In the overall patient population, the VGPR rate for zanubrutinib was 28.4% compared to 19.2% for ibrutinib.</li><li>In the relapsed/refractory population, the major response rate (partial response or better) was 78.3% for zanubrutinib and 80.2% for ibrutinib.</li><li>The safety profiles were generally similar.</li><li>Complete data will be submitted for presentation at a future medical conference.</li><li>ABBV is up a fraction premarket.</li><li>Related ticker: Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526409\" data-linked=\"BeiGene&#39;s zanubrutinib fails to beat Imbruvica in WM study; shares down 9% PM\" data-tweet=\"$BGNE $ABBV $JNJ - BeiGene&#39;s zanubrutinib fails to beat Imbruvica in WM study; shares down 9% PM https://seekingalpha.com/news/3526409-beigenes-zanubrutinib-fails-to-beat-imbruvica-in-wm-study-shares-down-9-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3526409-beigenes-zanubrutinib-fails-to-beat-imbruvica-in-wm-study-shares-down-9-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526408\" data-ts=\"1576504277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEXO\" target=\"_blank\">HEXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526408-hexo-down-8-premarket-on-q1-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HEXO down 8% premarket on Q1 miss</a></h4><ul><li>HEXO (<a href='https://seekingalpha.com/symbol/HEXO' title='HEXO Corp.'>HEXO</a>) <a href=\"https://seekingalpha.com/pr/17728507-hexo-corp-reports-financial-results-for-first-quarter-fiscal-2020\" target=\"_blank\">Q1 results</a> (C$): Gross cannabis revenue: 19.3M (+192.4%); Net revenue: 14.5M (+154.4%).</li><li>Net loss: (62.4M); loss/share: (0.24); CF Ops: (34.2M) (-64.4%).</li><li>Kg sold: 4,196.</li><li>Adult-use gross revenue per gram and gram equivalent sold: 4.35.</li><li>Launched Original Stash in Ontario.</li><li>Obtained Phase 1 licence for Belleville, sale of cannabis topicals, extracts, edibles and beverages licence for Gatineau facility, and a research licence for the Company.</li><li>Closed a $70M private placement of 8% unsecured convertible debentures.</li><li>Shares are down <font color=\"red\">8%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526364-hexo-misses-c-0_14-misses-on-revenue\" target=\"_blank\">HEXO misses by C$0.14, misses on revenue</a> (Dec. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526408\" data-linked=\"HEXO down 8% premarket on Q1 miss\" data-tweet=\"$HEXO - HEXO down 8% premarket on Q1 miss https://seekingalpha.com/news/3526408-hexo-down-8-premarket-on-q1-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3526408-hexo-down-8-premarket-on-q1-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526406\" data-ts=\"1576504032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MVIS\" target=\"_blank\">MVIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526406-microvision-seeks-nasdaq-hearing-for-delisting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MicroVision seeks Nasdaq hearing for delisting</a></h4><ul><li>MicroVision (NASDAQ:<a href='https://seekingalpha.com/symbol/MVIS' title='MicroVision, Inc.'>MVIS</a>) <a href=\"https://seekingalpha.com/pr/17728747-microvision-to-request-hearing-nasdaq-to-stay-delisting-action\" target=\"_blank\">will request</a> a hearing with the Nasdaq, which will delay the delisting action pending the panel's decision.</li><li>On December 12, MVIS received formal notice that the company would be delisted for non-compliance with the $1 bid price requirement.</li><li>MVIS shares are <font color=\"green\">up 3.7%</font> pre-market to $0.70.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526406\" data-linked=\"MicroVision seeks Nasdaq hearing for delisting\" data-tweet=\"$MVIS - MicroVision seeks Nasdaq hearing for delisting https://seekingalpha.com/news/3526406-microvision-seeks-nasdaq-hearing-for-delisting?source=tweet\" data-url=\"https://seekingalpha.com/news/3526406-microvision-seeks-nasdaq-hearing-for-delisting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526400\" data-ts=\"1576503361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526400-gilead-nash-candidates-flunk-mid-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead NASH candidates flunk mid-stage study</a></h4><ul><li>A Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03449446?cond=NASH+-+Nonalcoholic+Steatohepatitis&amp;lead=gilead+sciences&amp;phase=1&amp;draw=2&amp;rank=3\" target=\"_blank\">ATLAS</a>, evaluating Gilead Sciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) selonsertib, firsocostat and cilofexor, alone and in combination, in NASH (nonalcoholic steatohepatitis) patients with advanced fibrosis <a href=\"https://seekingalpha.com/pr/17728580-gilead-announces-topline-results-from-phase-2-atlas-study-in-patients-bridging-fibrosis-f3\" target=\"_blank\">failed to achieve the primary endpoint</a> of at least a one-stage improvement in fibrosis without worsening of NASH compared to placebo.</li><li>On a positive note, statistically significant effects in several secondary endpoints were observed for firsocostat + cilofexor versus control, including at least a two-point improvement in NAFLD Activity Score and at least a one-point reduction in steatosis, hepatocellular ballooning, lobular inflammation and certain tests of fibrosis, liver injury and function.</li><li>On the safety front, the most common adverse events related to firsocostat + cilofexor was mild-to-moderate pruritis (itchy skin) (28.2% vs 15.4% for placebo), headache, diarrhea and nausea.</li><li>Additional data will be submitted for presentation at a future medical conference.</li><li>Selonsertib failed an earlier Phase 3 study in NASH patients with compensated cirrhosis (<a href=\"https://seekingalpha.com/news/3431904-gileads-selonsertib-flunks-late-stage-nash-study\" target=\"_blank\">announced </a>in February).</li></ul><div class=\"tiny-share-widget\" data-id=\"3526400\" data-linked=\"Gilead NASH candidates flunk mid-stage study\" data-tweet=\"$GILD - Gilead NASH candidates flunk mid-stage study https://seekingalpha.com/news/3526400-gilead-nash-candidates-flunk-mid-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3526400-gilead-nash-candidates-flunk-mid-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526395\" data-ts=\"1576502873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/W\" target=\"_blank\">W</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526395-wayfairminus-3-after-morgan-stanley-turns-cautious\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wayfair -3% after Morgan Stanley turns more cautious</a></h4><ul> <li>Wayfair (NYSE:<a href='https://seekingalpha.com/symbol/W' title='Wayfair Inc.'>W</a>) is on watch after Morgan Stanley slashes its price target on the online retailer to $75 from $117 due to increased cost pressures it sees. The clipped price target stands well below the average sell-side PT of <a href=\"https://seekingalpha.com/symbol/W/ratings/sell-side-ratings\" target=\"_blank\">$105.83</a>.</li> <li>MS keeps Wayfair slotted at Equal-weight.</li> <li>Shares of Wayfair are <font color=\"red\">down 3.26%</font> premarket to $87.00 vs. the 52-week trading range of $78.59 to $173.72.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526395\" data-linked=\"Wayfair -3% after Morgan Stanley turns more cautious\" data-tweet=\"$W - Wayfair -3% after Morgan Stanley turns more cautious https://seekingalpha.com/news/3526395-wayfairminus-3-after-morgan-stanley-turns-cautious?source=tweet\" data-url=\"https://seekingalpha.com/news/3526395-wayfairminus-3-after-morgan-stanley-turns-cautious\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526394\" data-ts=\"1576502625\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526394-susquehanna-leaves-wdc-sidelines-on-5g-build\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna leaves WDC sidelines on 5G build</a></h4><ul><li>Susquehanna upgrades Western Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) from Neutral to Positive with a $90 price target, a 66% upside.</li><li>The firm expects the 5G smartphone build cycle to \"start in earnest\" towards the end of the March quarter.</li><li>The build will join cuts to NAND capex and wafer starts to create a light supply/demand balance by the June quarter.</li><li>Western Digital shares are <font color=\"green\">up 3.7%</font> pre-market to $56.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526394\" data-linked=\"Susquehanna leaves WDC sidelines on 5G build\" data-tweet=\"$WDC - Susquehanna leaves WDC sidelines on 5G build https://seekingalpha.com/news/3526394-susquehanna-leaves-wdc-sidelines-on-5g-build?source=tweet\" data-url=\"https://seekingalpha.com/news/3526394-susquehanna-leaves-wdc-sidelines-on-5g-build\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526391\" data-ts=\"1576502467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AUY\" target=\"_blank\">AUY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526391-yamana-gold-boosts-dividend-establishes-cash-reserve-fund\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yamana Gold boosts dividend, establishes cash reserve fund</a></h4><ul><li>Yamana Gold (NYSE:<a href='https://seekingalpha.com/symbol/AUY' title='Yamana Gold Inc.'>AUY</a>) <a href=\"https://seekingalpha.com/pr/17728527-yamana-gold-announces-25-dividend-increase-and-establishes-new-dividend-policy-to-ensure\" target=\"_blank\">boosts its dividend </a>by 25% to 5 cents per share annually, effective Q1 2020, following a 100% increase declared in Q3 2019.</li><li>AUY will also begin to report dividends on a per gold equivalent ounce of production basis \u2014 or GEO, with the latest increase bringing the dividend level to $50 per GEO.</li><li>Yamana is establishing a cash reserve fund that it will be able to draw upon, as required, gold prices decline and negatively impact margins over a period of time.</li><li>AUY <font color=\"green\">rises 1.3% </font>in premarket trading.</li><li>The company intends to maintain a balance in the reserve that can support the current or any future increased dividend for a minimum period, which may vary from time to time but is intended to be no less than three years, independent of prevailing gold prices.</li><li>While AUY expects to continue to generate cash flow that will form and add to the fund, it's also advancing monetization initiatives that will generate additional cash, some or all of which may add to the cash reserve fund.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526391\" data-linked=\"Yamana Gold boosts dividend, establishes cash reserve fund\" data-tweet=\"$AUY - Yamana Gold boosts dividend, establishes cash reserve fund https://seekingalpha.com/news/3526391-yamana-gold-boosts-dividend-establishes-cash-reserve-fund?source=tweet\" data-url=\"https://seekingalpha.com/news/3526391-yamana-gold-boosts-dividend-establishes-cash-reserve-fund\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526387\" data-ts=\"1576502053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACAD\" target=\"_blank\">ACAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526387-goldman-likes-amgen-and-unitedhealth-group-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman likes Amgen and UnitedHealth Group in premarket analyst action</a></h4><ul><li>ACADIA Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a>) initiated with Buy rating and $60 (35% upside) price target at Guggenheim. Shares up a fraction premarket.</li><li>Aurora Cannabis (NYSE:<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a>) initiated with Sell rating at GLJ Research.</li><li>Pluristem Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics Inc.'>PSTI</a>) initiated with Buy rating and $12 (252% upside) price target at Dawson James Securities.</li><li>Relmada Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RLMD' title='Relmada Therapeutics, Inc.'>RLMD</a>) initiated with Buy rating and $64 (87% upside) price target at Guggenheim. Shares up <font color=\"green\">17% </font>premarket.</li><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) (<font color=\"green\">+1%</font>) and UnitedHealth Group (NYSE:<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Incorporated'>UNH</a>) (<font color=\"green\">+2%</font>) added to Goldman Sachs Conviction Buy List.</li><li>Correvio Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CORV' title='Correvio Pharma Corp.'>CORV</a>) upgraded to Hold at Bloom Burton &amp; Co. Shares up <font color=\"green\">5%</font> premarket.</li><li>Cardinal Health (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health, Inc.'>CAH</a>) downgraded to Neutral at Guggenheim. Shares down <font color=\"red\">1%</font> premarket.</li><li>NextGen Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/NXGN' title='NextGen Healthcare, Inc.'>NXGN</a>) downgraded to Underweight with a $12 (19% downside risk) price target at Morgan Stanley. Shares down <font color=\"red\">2%</font> premarket.</li><li>Regeneron Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) downgraded to Inline with a $381 (1% upside) price target at Evercore ISI. Shares down <font color=\"red\">1% </font>premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526387\" data-linked=\"Goldman likes Amgen and UnitedHealth Group in premarket analyst action\" data-tweet=\"$ACAD $ACB $PSTI - Goldman likes Amgen and UnitedHealth Group in premarket analyst action https://seekingalpha.com/news/3526387-goldman-likes-amgen-and-unitedhealth-group-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3526387-goldman-likes-amgen-and-unitedhealth-group-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526386\" data-ts=\"1576501530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTI\" target=\"_blank\">BTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526386-british-american-tobaccoplus-4-after-baml-turnaround\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">British American Tobacco +4% after BAML turnaround</a></h4><ul> <li>British American Tobacco (NYSE:<a href='https://seekingalpha.com/symbol/BTI' title='British American Tobacco p.l.c.'>BTI</a>) races higher after landing a two-notch upgrade from Bank of America Merrill Lynch.</li> <li>The firm lifts BAT straight to Buy from Underperform on a more favorable view of the competitive environment for the tobacco company.</li> <li>Shares of British American Tobacco are <font color=\"green\">up 4.33%</font> in London trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526386\" data-linked=\"British American Tobacco +4% after BAML turnaround\" data-tweet=\"$BTI - British American Tobacco +4% after BAML turnaround https://seekingalpha.com/news/3526386-british-american-tobaccoplus-4-after-baml-turnaround?source=tweet\" data-url=\"https://seekingalpha.com/news/3526386-british-american-tobaccoplus-4-after-baml-turnaround\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526381\" data-ts=\"1576501218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONVO\" target=\"_blank\">ONVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526381-organovo-to-merge-tarveda-therapeutics-shares-up-21-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Organovo to merge with Tarveda Therapeutics; shares up 21% premarket</a></h4><ul> <li>Organovo Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ONVO' title='Organovo Holdings, Inc.'>ONVO</a>) is up <font color=\"green\">21%</font> premarket on entering into a <a href=\"https://seekingalpha.com/pr/17728443-organovo-and-tarveda-therapeutics-announce-definitive-merger-agreement\" target=\"_blank\">merger agreement</a> with Tarveda Therapeutics, a privately-held, clinical stage biopharmaceutical company.</li><li>Under the terms of the agreement, Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction. The merged company would operate under the name Tarveda Therapeutics, and trade on Nasdaq under the ticker symbol \u201cTVDA.\u201d</li><li>It is anticipated that Tarveda and Organovo stockholders will own ~75% and ~25% of the combined company, respectively. The merger is anticipated to close in Q1 2020.</li>  <li>Following the closing of the transaction, Tarveda intends to advance its two clinical stage oncology programs, PEN-866 and PEN-221, and further develop novel conjugates from its proprietary miniature drug conjugate platform.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3526381\" data-linked=\"Organovo to merge with Tarveda Therapeutics; shares up 21% premarket\" data-tweet=\"$ONVO - Organovo to merge with Tarveda Therapeutics; shares up 21% premarket https://seekingalpha.com/news/3526381-organovo-to-merge-tarveda-therapeutics-shares-up-21-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3526381-organovo-to-merge-tarveda-therapeutics-shares-up-21-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526379\" data-ts=\"1576501140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRL\" target=\"_blank\">CRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526379-charles-river-labs-to-acquire-hemacare-for-380m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charles River Labs to acquire HemaCare for $380M</a></h4><ul><li>Aimed at expanded its footprint in cell therapies, Charles River Laboratories (NYSE:<a href='https://seekingalpha.com/symbol/CRL' title='Charles River Laboratories International, Inc.'>CRL</a>) has <a href=\"https://seekingalpha.com/pr/17728440-charles-river-laboratories-to-acquire-hemacare-corporation\" target=\"_blank\">agreed to acquire</a> human-derived cellular products maker HemaCare (<a href='https://seekingalpha.com/symbol/HEMA' title='HemaCare Corporation'>OTCPK:HEMA</a>) for ~$380M in cash ($25.40 per share).</li><li>The transaction, expected to close next quarter, will add at least $50M to CRL's 2020 revenue while being neutral to non-GAAP EPS.</li><li>HemaCare closed at $20.00 on Friday.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526379\" data-linked=\"Charles River Labs to acquire HemaCare for $380M\" data-tweet=\"$CRL $HEMA - Charles River Labs to acquire HemaCare for $380M https://seekingalpha.com/news/3526379-charles-river-labs-to-acquire-hemacare-for-380m?source=tweet\" data-url=\"https://seekingalpha.com/news/3526379-charles-river-labs-to-acquire-hemacare-for-380m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526368\" data-ts=\"1576500386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WVE\" target=\"_blank\">WVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526368-wave-craters-59-premarket-on-exit-from-dmd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wave craters 59% premarket on exit from DMD</a></h4><ul><li>Wave Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/WVE' title='Wave Life Sciences Ltd.'>WVE</a>) plummets <font color=\"red\">59%</font> premarket on light volume in reaction to its decision to <a href=\"https://seekingalpha.com/pr/17728480-wave-life-sciences-announces-discontinuation-of-suvodirsen-development-for-duchenne-muscular\" target=\"_blank\">stop development</a> of suvodirsen for the treatment of Duchenne muscular dystrophy &#40;DMD&#41; in patients amenable to exon 51 skipping.</li><li>The company made its decision after interim results from a Phase 1 study failed to show a change from baseline in dystrophin expression.</li><li>Two other suvodirsen trials, on open-label extension study and Phase 2/3 DYSTANCE 51, will be terminated as well.</li><li>The company is also axing development of WVE-N531 for the potential treatment of DMD patients amenable to exon 53 skipping, representing a complete exit from DMD.</li><li>DMD leader Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) is up <font color=\"green\">2% </font>premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526368\" data-linked=\"Wave craters 59% premarket on exit from DMD\" data-tweet=\"$WVE $SRPT - Wave craters 59% premarket on exit from DMD https://seekingalpha.com/news/3526368-wave-craters-59-premarket-on-exit-from-dmd?source=tweet\" data-url=\"https://seekingalpha.com/news/3526368-wave-craters-59-premarket-on-exit-from-dmd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526366\" data-ts=\"1576500112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526366-micron-lifted-on-memory-tailwinds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron lifted on memory tailwinds</a></h4><ul><li>Morgan Stanley raises its Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) target from $48 to $56, citing the \"surprising\" recent strength in memory chip trends, which should provide short-term momentum for the company.</li><li>Analyst Joseph Moore: \"The news flow should be positive in the short term, and we do think there is still a positive trading opportunity in the stock in the next 3 months.\"</li><li>Moore remains on the Micron sidelines ahead of the next earnings report on December 18. The company signaled some EPS pressure for the quarter due to seasonality and \"NAND cost issues.\"</li><li>Micron shares are <font color=\"green\">up 3.1%</font> pre-market to $52.79.</li><li>MU has a Bullish average <a href=\"https://seekingalpha.com/symbol/MU/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526366\" data-linked=\"Micron lifted on memory tailwinds\" data-tweet=\"$MU - Micron lifted on memory tailwinds https://seekingalpha.com/news/3526366-micron-lifted-on-memory-tailwinds?source=tweet\" data-url=\"https://seekingalpha.com/news/3526366-micron-lifted-on-memory-tailwinds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}